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ABSTRACT
RIBOSOME MATURATION IN YEAST MODELS OF DIAMOND-BLACKFAN
ANEMIA AND SHWACHMAN-DIAMOND SYNDROME
Joseph B. Moore IV
April 12, 2010
The inherited bone

marrow failure

syndromes

(IBMFS) encompass a

heterogeneous collection of rare disorders characterized by hematological abnormalities,
generalized growth delays, and an increased incidence of malignant transformation.
These disorders include:

Diamond-Blackfan anemia (DBA), Shwachman-Diamond

syndrome (SDS), cartilage-hair hypoplasia (CHH), and dyskeratosis congenita (DC).
Despite sharing overarching similarities, each of these disorders manifests distinct
clinical phenotypes. Similar to their clinical features, the molecular underpinnings of the
IBMFS have characteristics that are both shared and distinctive. Aberrations in ribosome
synthesis have been associated with each of the IBMFS providing a common molecular
target for pathogenic mutations in disease related genes. In some cases, the ribosome
appears to be the major target of pathogenic lesions, whereas in others, effects on
ribosome synthesis are secondary and appear to have a modifying influence on disease
presentation.

For example, the primary target of pathogenic lesions in dyskeratosis

congenita is telomerase which distinguishes it from other IBMFS. The X-linked form of
dyskeratosis congenita, however, affects both telomerase function and ribosome synthesis
and is considerably more severe than the somatic forms of the disease that only affect
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telomerase. Thus, differences in primary targets of pathogenic lesions can account for
the distinct clinical presentations of certain mMFS. In other cases, where ribosome
synthesis appears to be the major target of disease causing mutations, the basis for
diverse clinical manifestations remains unknown.
The body of work presented in this dissertation is focused on ShwachmanDiamond syndrome and Diamond-Blackfan anemia, two mMFS where defects in
ribosome synthesis appear to underlie disease pathophysiology. The approach was to use
yeast models of both diseases to explore mechanisms by which ribosome synthesis was
affected using the 60S ribosomal subunit as a common molecular target. My studies
revealed that 60S subunit biogenesis was affected by distinct mechanisms in the two
disease models and that these differences may provide the molecular underpinnings for
the distinct clinical presentations observed in DBA and SDS patients. Further studies on
the mechanism by which 60S subunit biogenesis was affected in the SDS model have
clear implications for the treatment of this disorder.
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CHAPTER I
FROM RIBOSOMES TO MARROW FAILURE

General Introduction
Ribosomal Defects as a Causative Agent in Marrow Failure
Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome (SDS),
cartilage-hair hypoplasia (CHH), and dyskeratosis congenita (DC) are members of a rare
group of disorders recognized as the inherited bone marrow failure syndromes (IBMFS)
(Liu and Ellis 2006).

The members of this group are characterized by defective

hematopoiesis, enhanced cancer susceptibility, and a variable assortment of congenital
aberrations. While the IBMFS have these overarching similarities, each presents with
characteristic physical stigmata giving rise to distinct clinical presentations (Liu and Ellis
2006; Shimamura 2006; Ganapathi and Shimamura 2008). Faulty ribosome synthesis has
been observed in each of the IBMFS suggesting a common target, which initially
proffered explanation for their general overarching features. While having a common
molecular target could explain some of the universal characteristics of the IBMFS, it does
not account for their unique features. Studies on molecular etiology led to the discovery
that the target genes affected in some of the IBMFS were multifunctional and that they
had secondary effects on ribosome synthesis. Thus, the primary process affected by the
pathogenic lesion could account for distinct clinical phenotypes in a number of these
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disorders. However, two of the IBMFS, DBA and SDS, both appear to have ribosome
synthesis as their primary molecular target raising the question of how defects in a
common molecular process can give rise to unique clinical manifestations.

The Cell's Translational Machinery
Ribosomes: Structure and Function
Ribosomes are responsible for the translation of genome encoded messenger
RNAs (mRNA) into protein. The structure and function of ribosomes, as well as the
fundamental pathway of rRNA synthesis, look to be significantly conserved among all
kingdoms (Hage and Tollervey 2004). Translationally competent ribosomes require the
union of both a small ribosomal subunit (bacterial 30S or eukaryotic 40S) and a large
ribosomal subunit (bacterial 50S or eukaryotic 60S).

The small subunit is primarily

responsible for mRNA binding and the identification of initiation codons.

Once an

initiation codon is identified as part of a 48S initiation complex, the large ribosomal
subunit joins and further steps in the translational process can commence (Hage and
Tollervey 2004). Structurally, these ribonucleoprotein (RNP) complexes are composed
of intricately arranged RNAs possessing numerous interactions with a network of
ribosomal proteins with approximately 60% of their composition being rRNA and the
other 40% ribosomal proteins (Moore 1997). A large majority of ribosomal proteins
(RPs) are rich in basic amino acids (i.e. lysine and arginine) and therefore are highly
positively charged. This property of RPs facilitates the stability of an otherwise sterically
unfavorable compact mass of rRNA by interacting and reducing the repulsive forces
imposed by the highly negatively charged rRNAs.
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Much of what is now understood concerning ribosome structure and catalytic
function has been elucidated from high resolution x-ray crystallographic structures of
bacterial and archaeal ribosomes (Steitz 2008). Atomic structures of the small and large
ribosomal subunits from eubacterium Thennus thermophilus (Schluenzen, Tocilj et al.
2000) and archaeon Haloarcula marismortui (Ban, Nissen et al. 2000), respectively, have
been elucidated. These crystallographic-based studies revealed that RPs primarily reside
at the ribosome's exterior.

These proteins frequently possess distinctively folded

extensions that project into the subunit's interior where they interact with RNA to
stabilize and interlock numerous rRNA domains (Ban, Nissen et al. 2000; Schluenzen,
Tocilj et al. 2000). These studies suggested ribosomal proteins to have a minimal role in
protein synthesis, a theory inferred previously from evolutionary consideration, as RPs
were shown to be largely deficient from both the subunit interface and the peptidyltransferase active site, major functional areas consisting of only RNA constituents (Ban,
Nissen et al. 2000; Schluenzen, Tocilj et al. 2000). Consistent with this view, "naked"
23S rRNA depleted of ribosomal proteins from Escherichia coli was shown to be capable
of catalyzing peptide bond formation in vitro, this further illustrating the notion that RP's
are not an absolute requirement for certain critical activities of the ribosome (Nitta, Veda
et al. 1998; Khaitovich, Tenson et al. 1999). The perception that the ribosome is a
ribozyme, or rather that its catalytic function is exclusively dependent upon its rRNA,
was finally confirmed by studying atomic structures of the large ribosomal subunit (from
Haloarcula marismortui) in complex with substrate analogs (Nissen, Hansen et al. 2000).

Steitz and colleagues demonstrated these substrate analogs interact with conserved rRNA
elements at the peptidyl-transferase active site and that ribosomal protein side-chain
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moieties were fairly distant, no closer than 18 angstroms, to the forming peptide bond at
the presumed peptidyl-transferase active site (Nissen, Hansen et al. 2000). Based on
these studies, it is now generally accepted that ribosomal proteins principally function in
maintaining the three-dimensional organization of the rRNA in forming the active sites
necessary for the myriad of activities involved in protein synthesis (Ban, Nissen et al.
2000; Nissen, Hansen et al. 2000; Schluenzen, Tocilj et al. 2000).

The Fundamentals of Ribosome Assembly
Despite sharing many general characteristics, the eukaryotic ribosome is
structurally and functionally more complex than its bacterial counterpart (Dinman 2009).
The fact that bacterial ribosomes have been successfully reconstituted in vitro from their
purified protein and rRNA components whereas eukaryotic ribosomes have not, further
illustrates this concept (Traub and Nomura 1968; Culver 2003).

Despite these

distinctions, the pathway of rRNA synthesis appears to be significantly conserved among
the two kingdoms, as does the structure and polarity of the rDNA operons from which
mature rRNAs are derived (Hage and Tollervey 2004). For example, in both kingdoms
the small and large subunit rRNAs are cotranscribed with the small subunit rRNA being
positioned upstream of the large subunit rRNAs. The mature rRNA species are then
liberated from their primary pre-rRNA transcript by a coordinated series of endo- and
exonucleolytic cleavage reactions. Despite these similarities, however, the intricacies of
ribosome assembly appear to be quite distinct among bacteria and eukaryotes.
In bacteria, a single RNA polymerase is responsible for synthesizing the cell's
rRNA, whereas in eukaryotes, RNA polymerases I and III are responsible for the
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transcription of the 35S pre-rRNA and 5S rRNA, respectively.

In the bacterium

Escherichia coli, numerous rRNA processing and modifying enzymes, as well as a small

number of non-ribosomal factors (i.e. putative helicases, GTPases, putative RNA
chaperones, and protein chaperones), have been identified to participate in the ribosome
assembly process (Srivastava and Schlessinger 1990; Nierhaus 1991; Culver 2003).
Intriguingly, all of these non-ribosomal factors have been shown to be dispensable for
ribosome assembly, suggesting that they simply facilitate a spontaneous process (Dinman
2009). The bacterial ribosome is thought to assemble via an "assembly gradient," where
ribosomal protein interactions are coupled to rRNA folding and maturation, in a process
that is largely co-transcriptional (Figure 1, top panel) (Lewicki, Margus et al. 1993). In
contrast, eukaryotic pre-rRNA processing and modifications are largely posttranscriptional and require a substantial number of non-structural or trans-acting factors
(Figure 1, bottom panel).

For example, the proper assembly of the -80 ribosomal

proteins with four rRNAs (18S, 5.8S, 25S, and 5S) to form yeast ribosomes requires over
240 trans-acting factors, which include approximately 170 non-ribosomal proteins and
over 70 small nucleolar rRNAs (snoRNAs). Moreover, the majority of these trans-acting
factors are essential for ribosome assembly and function (Venema and Tollervey 1999).
In addition to an already inherently complex ribosome assembly program, eukaryotes
have the added issue of subcellular compartmentalization, a challenge the prokaryotic cell
does not contend with. In yeast and other eukaryotes, rRNA transcription occurs in the
nucleolus, as do the initial steps of ribosome synthesis and rRNA modification. The
resultant pre-ribosomes are eventually transported to the nucleoplasm, where they
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undergo additional steps of maturation, and subsequently to the cytoplasm where the
process is completed (Fromont-Racine, Senger et al. 2003).
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Figure 1. Ribosome maturation in E. coli and S. cerevisiae. Top panel, E. coli
ribosome maturation is largely a co-transcriptional process whereas the binding of
ribosomal proteins is coupled to rRNA folding and maturation. The mature 16S and 23S
rRNAs are cleaved from the nascent transcript by RNase III. Bottom panel, in yeast the
35S pre-rRNA nascent transcript systematically interacts with ribosomal proteins and
assembly factors, starting with small subunit proteins and related processing factors that
assist with rRNA folding. The nascent 35S pre-rRNA is cleaved by RNase III (Rntlp)
and is post-transcriptionally modified by numerous snoRNPs. The "earliest detectable"
90S pre-ribosome particle consists of 35S pre-rRNA, small ribosomal subunit proteins,
non-ribosomal assembly factors, and the U3 snoRNP. With the addition of large subunit
RPs, the 90S particle is further processed leading to the formation of 66S and 43S
particles, which give rise to mature 60S and 40S ribosomal subunits, respectively. Figure
adapted from Rage and Tollervey 2004.
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Yeast: A Model Organism for the Study of Eukaryotic Ribosome Biogenesis
Ribosome assembly has been extensively studied and is best characterized in the
budding yeast Saccharomyces cerevisiae (Venema and Tollervey 1999; Fatica and
Tollervey 2002; Fromont-Racine, Senger et al. 2003; Dinman 2009).

As previously

noted, this process begins with RNA polymerase I mediated transcription of the 35S prerRNA transcript and rapid snoRNA guided, site-specific modifications.

These

modifications include box CID snoRNA-mediated 2'-hydroxyl ribose methylation (the
most prevalent of the modifications) and box HlACA snoRNA-mediated isomerization of
uridine to pseudouridine (41).

Early yeast labeling experiments suggested that

methylation events did not occur co-transcriptionally, but instead occurred immediately
following transcription (Udem and Warner 1972). These nucleotide modifications appear
to be clustered in functional rRNA regions and tend to be vacant from regions where
ribosomal proteins bind (Decatur and Fournier 2002). Their biological purposes are not
clear, but these modifications have been proposed to be involved in rRNA stabilization
by acting as a "molecular mortar" to secure structural domains, and to play a role in
enhancing the ribosome's translational activity by fine-tuning its function (Kowalak,
Bruenger et al. 1995; Green and Noller 1996; Nissen, Hansen et al. 2000). The 35S prerRNA is located within a 90S pre-ribosome particle inside the nucleolus, which contains
the U3 small nucleolar ribonucleoprotein complex, an extensive number of small
ribosomal subunit proteins, and non-ribosomal factors, all of which are assembled cotranscriptionally.

Recent evidence suggests that 5S rRNA, together with other large

ribosomal subunit proteins, is also recruited and integrated into the 90S pre-ribosomal
particle early in the assembly program (Zhang, Harnpicharnchai et al. 2007). From this
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juncture, the 35S transcript subsequently undergoes a series of nucleolytic cleavage
events which commence near the 5' end of the pre-rRNA (outlined in Figure 2).
The initial steps in this process involve the sequential endonucleolytic cleavage of
sites Ao and AI within the 5' external transcribed sequence (5' ETS), which leads to the
formation of 33S and 32S pre-rRNA species, respectively.

The next step is an

endonucleolytic cleavage at site A2 which results in the division of the 90S particle into
43S and 66S pre-ribosomal particles containing 20S and 27S A2 pre-rRNAs, respectively.
The 43S precursor is ultimately transported to the cytoplasm where it matures, via
endonucleolytic cleavage of site D, to a functionally competent 40S ribosomal subunit
containing mature I8S rRNA.

The 27S A2 pre-rRNA proceeds via two alternative

processing pathways that generate mature 5.8S and 25S rRNAs, components of the 60S
ribosomal subunit. Approximately 85% of the 27S A2 pre-rRNA species are cleaved at
site A3 via RNase MRP followed by 5' to 3' exonucleolytic digestion (by Ratip
exonuclease) to site BIS, while the other 15% of the 27S A2 pre-rRNA species are cleaved
at site B IL ; both precursors are eventually subjected to endonucleolytic cleavage of site
B2. From these reactions two 27S B pre-rRNA species are formed, 27S Bs (short) and
27S BL (long), the significance of which is currently unknown. Both of these pre-rRNA
species undergo further processing at sites C I and C 2 , as well as exosome mediated 3' to
5' exonucleolytic digestion to site E, finally generating the mature 5.8S (long and short
species) and 25S rRNA constituents of the 60S ribosomal subunit.
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11

In addition to nucleotide modification and rRNA processmg, the nascent
ribosome undergoes a complex senes of remodeling steps that are driven by the
coordinated binding of different ribosomal proteins, and by the organized association and
dissociation of trans-acting assembly factors (Venema and Tollervey 1999; Dinman
2009).

Many of these trans-acting factors include GTPases, ATP dependent RNA

helicases, AAA-ATPases, and chaperones. This pathway advances with the development
of distinct ribosome assembly intermediates; with the earliest detectable intermediate
being the 90S pre-ribosomal particle.

The composition of the early 90S particle is

distinct from later pre-40S and pre-60S ribosomes. For instance, the 90S particle is rich
in 40S processing factors, but notably deficient in those required for 60S subunit
assembly (Fromont-Racine, Senger et al. 2003). This suggests that 60S subunit assembly
factors associate much later in the ribosome maturation process and explains why
disruption of early pre-rRNA processing (i.e. Ao-A2 cleavage events) does not
significantly interfere with the production of 60S ribosomal subunits (Grandi, Rybin et al.
2002).
As previously noted, the early 90S ribosome is rapidly converted to 43S and 66S
assembly intermediates within the nucleolus (Udem, Kaufman et al. 1971; Trapman,
Retel et al. 1975).

The 43S pre-ribosome is exported to the cytoplasm where it is

completely matured and activated via a final rRNA cleavage event. Maturation of the
66S pre-ribosome is far more complicated than that of the early 43S particle.

For

instance, prior to its nuclear export to the cytoplasm, the 66S particle undergoes
numerous remodeling and rRNA processing steps involving the development of
approximately five 66S intermediates while en route from the nucleolus to the
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nucleoplasm. Presumably, 60S subunit pre-rRNA processing is largely complete in the
nucleoplasm and contains mature 25S, 5.8S, and 5S rRNAs prior to the pre-60S subunit's
export to the cytoplasm.
Both large and small subunits are independently exported through nuclear pore
complexes, a process which is facilitated via the export receptor XpollCrml and
RanGTP (Johnson, Ho et al. 2001; Moy and Silver 2002; Thomas and Kutay 2003).
Although much is unknown concerning subunit nuclear export, genetic studies in yeast
have identified a few trans-acting factors that are essential for this process. For instance,
prior to attaining export competence, 60S subunits must bind ribosomal protein LlO,
which in turn binds the Nmd3 adaptor protein providing the nuclear export signal (NES),
which is finally recognized by the Xpol/Crml export receptor protein (Ho, Kallstrom et
al. 2000; Gadal, Strauss et al. 2001; Senger, Lafontaine et al. 2001). During nuclear
export, ribosomal subunits contain a limited number of non-ribosomal proteins.

In

addition to Nmd3, these factors include the anti-association factor Tif6, and an
uncharacterized protein Arxl. These proteins are absent from ribosomes that are actively
engaged in translation (Hung and Johnson 2006).

Thus, during the late cytoplasmic

stages of 60S ribosomal subunit maturation, translational competency is achieved after
their dissociation.

These factors are then recycled back to the nucleus, where they

participate in additional rounds of nuclear export (Hung and Johnson 2006). It is likely
that factors residing in the cytoplasm play an active role in this process of ribosome
activation and nuclear export factor recycling.

A significant number of studies have

shown that two proteins, Efll and Sdol may also be involved in 60S subunit activation
(Becam, Nasr et al. 2001; Senger, Lafontaine et al. 2001; Menne, Goyenechea et al.
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2007). Efll is a cytoplasmic GTPase whereas Sdo 1 is the yeast ortholog of SBDS, the
protein responsible for SDS. Genetic studies in yeast have positioned these factors in the
late cytoplasmic steps of 60S subunit maturation where Sdo 1 appears to function in
concert with Efll to promote Tif6 release, allowing for subsequent subunit joining
(Menne, Goyenechea et al. 2007).

Ribosome Synthesis is Regulated at Multiple Levels
Ribosome biogenesis is a highly regulated process and is closely associated with
both cell growth and proliferation (Ruggero and Pandolfi 2003).

Rates of ribosome

production are rapidly increased in response to various stimuli such as alterations in
nutrient availability and mitogenic stimulation.

Increases in ribosome numbers are

ultimately dependent upon the rate of synthesis of ribosomal RNA and proteins, both of
which are mediated by posttranslational modification of specific transcription factors that
modulate Polymerase I and Polymerase III activity. A key regulator of the transcriptional
activity of RNA Pol I is the transcription factor UBF (upstream binding factor)
(Beckmann, Chen et al. 1995; Cavanaugh, Hempel et al. 1995; Brandenburger, Jenkins et
al. 2001). UBF is directly targeted by several serine/threonine kinases, as well as tumor
suppressor proteins (i.e. RB and p53), which can enhance or repress UBF activity thereby
influencing cellular rates of rRNA synthesis (O'Mahony, Xie et al. 1992; Voit, Schnapp
et al. 1992; Voit, Kuhn et al. 1995; Ruggero and Pandolfi 2003).
Enhanced ribosome production in response to growth factors and nutrient
signaling also involves the enhanced translation of a series of mRNAs containing 5'
terminal oligopyrimidine tracts (5'-TOP) via an unknown mechanism (Ruggero and
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Pandolfi 2003).

The 5'-TOP containing genes encode elongation factors, ribosomal

proteins, and ribosome biogenesis factors. The pathway(s) mediating their regulation is
unknown, however, the earliest events identified following mitogenic stimuli is the
phosphorylation of Rps6 via S6 kinases S6Kl and S6K2 (Tang, Hornstein et al. 2001).
Experiments correlating mitogen stimulation with the S6Kl-mediated phosphorylation of
Rps6 and concomitant enhanced translational efficiency of 5'-TOP containing messages,
led to the proposal that phosphorylation of ribosomal protein S6 increases the affinity of
ribosomes for 5'-TOP containing messages (Thomas 1986; Jefferies, Reinhard et al.
1994; Jefferies and Thomas 1994).

Although a number of correlative studies have

supported this model, the translational control of 5'-TOP mRNAs is purely speculative
and has not been experimentally validated to be mediated by S6K1. A more recent study
challenges this paradigm and suggests an alternate means of 5'-TOP gene expression that
is dependent on the phosphotidyl inositol 3-kinase (PI3K) signaling pathway, and
independent of both S6 kinase activity and the phosphorylation status of Rps6 (Stolovich,
Tang et al. 2002).

Despite this debate, it appears that ribosome biogenesis is under

multiple modes of regulation, which involves both transcriptional and translational
control mechanisms.
Indeed, proper ribosome assembly and regulation is crucial to the health of the
cell. Perturbations in the ribosome biosynthetic pathway as well as circumstances of
unregulated cell growth (i.e. oncogenesis) require growth arrest or apoptosis to assist in
the elimination of affected cells. Not surprisingly, a growing body of evidence suggests
that the tumor suppressor proteins RB (retinoblastoma) and p53 play an important role in
mediating these processes. For instance, both RB (Cavanaugh, Hempel et al. 1995; Voit,
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Schafer et al. 1997; Ciarmatori, Scott et al. 2001) and p53 (Budde and Grummt 1999;
Zhai and Comai 2000) negatively regulate Pol I and Pol III activity by interfering with
transcriptional complex formation at the promoter regions of genes encoding rRNA and
non-coding RNAs (5S rRNA, snoRNAs, & tRNA), respectively, thereby repressing
ribosome biogenesis and subsequent protein synthesis (Ruggero and Pandolfi 2003). The
hindrance of transcriptional complex assembly, as mediated by RB and p53, is
accomplished via their direct interactions with key transcription factors (i.e. UBF, TIFlB/SLI, TFIIIB) (Ruggero and Pandolfi 2003).

The p19ARF tumor suppressor also

negatively regulates ribosome biogenesis by blocking rRNA synthesis and processing
(Sugimoto, Kuo et al. 2003). The enhanced expression of these tumor suppressors in
response to stress signals results in repression of ribosome biogenesis and cell cycle
inhibition (Liu and Ellis 2006). The tumor suppressor p53 can also detect aberrations in
rRNA processing/synthesis or perturbations in ribosome assembly and inhibit cell cycle
progression or induce apoptosis (Ashcroft, Taya et al. 2000; Pestov, Strezoska et al.
2001). These stress response pathways, involving the activation of p53 in response to
defects in ribosome biogenesis, have great implications for the mechanisms underlying
the pathophysiology of disorders linked to defects in ribosome biogenesis, especially
Diamond-Blackfan anemia and Shwachman-Diamond syndrome.
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Diamond-Blackfan Anemia

Historical Introduction and Clinical Features
In 1938, Harvard Medical School physicians, Louis K. Diamond and Kenneth D.
Blackfan, first described congenital erythroid hypoplastic anemia, a disorder which was
later termed as Diamond-Blackfan anemia (DBA; OMIM 105650). Almost two decades
later, Diamond and colleagues published work detailing their 25 year longitudinal studies
of 30 patients with congenital hypoplastic anemia, and it was with these studies where the
first association between DBA and skeletal abnormalities was noted (Diamond. Allen et
al. 1961). As these early studies indicated, DBA, like many other bone marrow failure
syndromes, is a complex disease presenting with a multitude of symptoms which include
both hematologic and nonhematologic manifestations. DBA is clinically defined as a
pure red cell hypoplasia leading to anemia, though the involvement of additional
hematopoietic lineages have been reported (Giri, Kang et al. 2000; Vlachos, Federman et
al. 2001; Lipton and Ellis 2009). DBA typically presents in early infancy manifesting
symptoms of anemia with macrocytosis, reticulocytopenia, and normocellular bone
marrow with a deficiency of red cell progenitors (Diamond, Wang et al. 1976; Dokal and
Vulliamy 2008). Additional supportive features of a DBA diagnosis include elevated
fetal hemoglobin levels and raised erythrocyte adenosine deaminase (eADA) activity; the
physiological significance of these associated increases are unknown (Dokal, Rule et al.
1997; Lipton and Ellis 2009).
The incidence of cancer in DBA patients is relatively low compared to other
IBMFS, but is substantially higher than that observed in healthy individuals.

Both

hematological (i.e. MDS and AML) and non-hematological (i.e. osteosarcoma, breast
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cancer, hepatocellular carcinoma) malignancies have been identified in DBA patients
(Lipton and Ellis 2009). Reports from the Diamond-Blackfan Anemia Registry (DBAR)
show solid tumors are more prevalent among DBA patients compared to other
malignancies (Lipton, Federman et al. 2001). In addition to an increased incidence of
cancer, approximately one-third of patients exhibit somatic abnormalities such as
craniofacial anomalies (cleft lip, palate), triphalangeal thumbs, genitourinary system
defects, and cardiac irregularities (Lipton, Atsidaftos et al. 2006; Dokal and Vulliamy
2008; Ganapathi and Shimamura 2008; Lipton and Ellis 2009).

The Ribosome is a Target of Many Pathogenic Mutations in DBA
Diamond-Blackfan anemia has an autosomal-dominant mode of inheritance. In
1999, 42 out of 172 DBA patients were found to harbor disease-associated pathogenic
mutations in a gene locus encoding a small ribosomal subunit protein, Rps 19
(Draptchinskaia, Gustavsson et al. 1999). Interestingly, DBA represents the first and
only known inherited disease resulting from mutations in a structural component of the
ribosome. DBA is often referred to as a "ribosomapathy," a term which describes a
disorder resulting from a failure to produce adequate quantities of ribosomes (Dianzani
and Loreni 2008). This term gained even greater acceptance with the emergence of other
mutated ribosomal proteins in DBA. Currently, of the 80 structural proteins comprising
the human ribosome, nine have been identified as mutant in approximately 50% of DBA
patients (Dianzani and Loreni 2008). These ribosomal proteins include both small and
large ribosomal subunit proteins: Rps7 (Gazda, Sheen et al. 2008), RpslO (Doherty,
Sheen et al. 2010), Rps17 (Cmejla, Cmejlova et al. 2007), Rps19 (Draptchinskaia,
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Gustavsson et al. 1999), Rps24 (Gazda, Grabowska et al. 2006), Rps26 (Doherty, Sheen
et al. 2010), Rpl5 (Gazda, Sheen et al. 2008), Rp111 (Gazda, Sheen et al. 2008), and
Rpl35A (Farrar, Nater et al. 2008). Most of these ribosomal proteins, in both yeast and
mammalian cells, are required for the biogenesis of their respective subunits (Choesmel,
Bacqueville et al. 2007; Flygare, Aspesi et al. 2007; Idol, Robledo et al. 2007; Farrar,
Nater et al. 2008; Gazda, Sheen et al. 2008). As mutations in these genes only account
for approximately 50 percent of reported cases of DBA, there are undoubtedly a number
of other genetic targets yet to be discovered. Efforts are currently underway to sequence
all 80 ribosomal subunit protein genes in DBA patients from the North American DBA
registry, a project which is being led by a consortium of DBA investigators in
collaboration with the NHLBI Resequencing and Genotyping Service.
Most of the genetic mutations linked to DBA are heterozygous loss-of-function
mutations which result in gene product haploinsufficiency.

RPS19 is the gene most

commonly mutated in DBA and accounts for approximately 25% of all of the reported
cases. For this reason, RPS19 has been extensively studied and a total of 77 diseaserelated mutations have been described in the literature (Campagnoli, Ramenghi et al.
2008). These mutations include translocations, gene deletions, truncation mutations (i.e.
nonsense or frameshift), and missense mutations (Campagnoli, Ramenghi et al. 2008;
Dianzani and Loreni 2008).

In vitro studies following the fate of mutated Rps 19

demonstrate various mutations to decrease protein stability or lead to alterations in
nucleolar localization (Angelini, Cannata et al. 2007; Cretien, Hurtaud et al. 2008). In
each case, these mutant Rps 19 proteins are incapable of being assembled into functional
ribosomes (Angelini, Cannata et al. 2007).

19

DBA Etiology and Pathophysiology
Pioneering work in DBA provided evidence that its characteristic red cell
hypoplasia was the result of an intrinsic disorder of erythropoiesis.

Freedman and

colleagues (1976) showed that a small number of DBA patients had reduced amounts of
early committed myeloid progenitors in bone marrow aspirates (Freedman, Amato et al.
1976). These observations were re-enforced by another group of investigators based in
Boston, who showed a reduction in committed erythroid precursors (both erythroid burstforming units [BFU-E] and erythroid colony-forming units [CFU-E]) in eleven DBA
patients. These authors concluded that these reductions were a consequence of a delay in
differentiation prior to the earliest committed phase of erythroid development (BFU-E)
(Nathan, Clarke et al. 1978). While a number of these earlier studies highlighted a
paucity of red cell precursors in DBA, later investigation revealed a number of DBA
patients to possess marrow with normal numbers of both BFU-E and CFU-E myeloid
progenitors, however their differentiation to mature erythrocytes was interrupted (Lipton,
Kudisch et al. 1986).

These data, although contradictory, suggest that DBA is a

heterogeneous disorder and further supports it as a disease which results from an intrinsic
progenitor defect - a defect which later studies propose related to both impaired
differentiation and reduced proliferative capacity of red cell precursors (Flygare, Kiefer et
al. 2005; Miyake, Flygare et al. 2005).
Molecular studies investigating DBA pathophysiology lagged for some time as in
vivo animal models, which recapitulate the human disease phenotype, were not available

and initial attempts to construct them were unsuccessful. The first reported DBA mouse
model was developed in 2004 and utilized gene targeted disruption of murine RPS19
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(Matsson, Davey et al. 2004). Mice heterozygous for this RPS19 null allele had no
observable disease phenotype and mice which were homozygous for the null allele were
early embryonic lethal (Matsson, Davey et al. 2004).

More recently, two groups

successfully created zebrafish models of DBA via the morpholino-mediated knockdown
of Rps19 (Danilova, Sakamoto et al. 2008; Uechi, Nakajima et al. 2008). Intriguingly,
both of these zebrafish models recapitulate certain characteristics of the human disease,
including defective erythropoiesis and developmental abnormalities.

Uechi and

colleagues (Uechi, Nakajima et al. 2008), in addition to RPS19, also investigated the
depletion of a myriad of other ribosomal proteins and demonstrated three others, one of
those being RPL35A (Farrar, Nater et al. 2008), to also affect erythropoiesis in zebrafish.
A large-scale chemical mutagenesis screen for mice with a dark skin phenotype (de
Angelis, Flaswinkel et al. 2000) led to the serendipitous identification of missense
mutations in RPS19 and RPS20, denoted as DSK3 and DSK4, respectively (McGowan,
Li et al. 2008). McGowan and colleagues demonstrated Rps19DSK3 heterozygous mice
manifest a mild DBA-like phenotype.
suffered from

These mice had normocellular marrow, but

a hypoproliferative-proapoptotic

anemia and growth retardation

(McGowan, Li et al. 2008). In light of the available data, the current view is that DBA is
the result of an intrinsic erythroid progenitor defect characterized by a proapoptotic
phenotype and an impaired capacity to differentiate (Lipton, Kudisch et al. 1986; Tsai,
Arkin et al. 1989; Perdahl, Naprstek et al. 1994; Ohene-Abuakwa, Orfali et al. 2005;
Miyake, Utsugisawa et al. 2008). Notably, the disease phenotypes observed in zebrafish
(Danilova, Sakamoto et al. 2008) and mouse (McGowan, Li et al. 2008) DBA models are
ameliorated by inactivating p53. Thus, it has been hypothesized that the proapoptotic
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phenotype of myeloid precursors observed in DBA is linked to p53 stabilization and
activation, referred to as the "ribosomal stress hypothesis (Dianzani and Loreni 2008)."
This hypothesis suggests that a reduction in ribosomal protein andlor rRNA synthesis
promotes the stabilization and concomitant activation of p53, an event which ultimately
results in premature cell senescence or apoptosis. These events are then thought to be
responsible for the observed clinical features associated with DBA (i.e. anemia,
developmental delays, and malformations) (Dianzani and Loreni 2008).
A potential mechanism by which abortive ribosome assembly or nucleolar stress
could signal to activate the p53 tumor suppressor involves the interaction of certain
ribosomal proteins with MDM2 (Murine Double Minute), the most central negative
regulator of p53. MDM2 is essential for maintaining low cellular levels of active p53 by
binding and blocking p53's transcriptional activity (Chen, Marechal et al. 1993; Ruggero
and Pandolfi 2003), inducing p53's nuclear export (Boyd, Tsai et al. 2000; Geyer, Yu et
al. 2000), and initiating p53's ubiquitination thereby promoting its proteasome-mediated
degradation. MDM2 mediates p53 degradation through its function as a RING fingercontaining E3 ubiquitin ligase (Haupt, Maya et al. 1997; Kubbutat, Jones et al. 1997).
Three large ribosomal subunit proteins (RpI5, Rp111, and Rp123) have been confirmed to
directly interact with MDM2, an interaction which is associated with a reduction in the
ubiquitin ligase activity of MDM2 and a concomitant stabilization of p53 (Marechal,
Elenbaas et aL 1994; Lohrum, Ludwig et al. 2003; Zhang, Wolf et al. 2003; Dai, Zeng et
al. 2004; Jin, Itahana et al. 2004). In addition, a small ribosomal subunit protein (Rps7)
has also been shown to interact with MDM2 and elicit the stabilization and activation of
p53, although with a weaker affinity than those of the large subunit (Chen, Zhang et al.
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2007). These interactions have mostly been investigated under conditions that disrupt the
assembly of both 40S and 60S ribosomal subunits, either by the inhibition of RNA
polymerase I activity or by genetic inactivation of rRNA processing enzymes (Perry and
Kelley 1970; Pestov, Strezoska et al. 2001; Yuan, Zhou et al. 2005). In the context of
these studies, ribosome biogenesis is disrupted at early stages which results in the
subsequent diversion of ribosomal proteins from their normal assembly pathway to other
fates within cells. Some studies suggest that ribosomal proteins synthesized in excess of
what is required for ribosome assembly are rapidly degraded by the proteasome (Lam,
Lamond et al. 2007). Despite this, sufficient evidence exists to indicate that ribosomal
proteins diverted from assembling into maturing ribosomal subunits can act as important
modulators of MDM2 activity leading to the stabilization and activation of p53. The
importance of p53 in ribosome stress pathways has been documented in zebrafish and
mouse models of DBA (Danilova, Sakamoto et al. 2008; McGowan, Li et al. 2008).
Thus, signaling through unassembled ribosomal proteins could potentially bridge the
divide between abortive ribosome assembly and the proapoptotic phenotype of erythroid
progenitors in DBA patients.
In addition to the inhibitory effects imposed by the binding of specific ribosomal
proteins to MDM2, the ability of MDM2 to target p53 can also be affected by its
interaction with the ARF tumor suppressor protein (Lindstrom, Deisenroth et al. 2007).
Interestingly, interactions between ARF and nucleophosmin (B23), a multifunctional
protein involved in ribosome synthesis and nuclear export, suggest an alternative pathway
in which nucleolar stress may induce p53 activation in DBA (Maggi, Kuchenruether et al.
2008).

It is believed that the relative amounts of ARF, MDM2, and B23 play an
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important role in coupling cell cycle regulation to ribosome biogenesis (Brady, Yu et al.
2004). The relative contribution of this pathway to DBA pathogenesis or the degree to
which it cooperates with other nucleolar stress signaling pathways, particularly those
involving ribosomal proteins liberated from abortively assembled intermediates, is
currently unknown.

Shwachman-Diamond Syndrome

Historical Introduction and Clinical Features
Shwachman-Diamond syndrome (SDS; OMIM 260400) was first identified in
1964 and so was named after two Harvard Medical School clinicians, Harry Shwachman
and Louis K. Diamond (also of Diamond-Blackfan anemia), who described it in five
patients suffering from leucopenia and pancreatic insufficiency (Shwachman, Diamond et
al. 1964). The clinical phenotype of SDS, which often manifests in infancy, is frequently
complex presenting with multi systemic anomalies that include abnormal myelopoiesis,
exocrine pancreatic insufficiency, skeletal abnormalities (i.e. metaphyseal dysostosis),
and cancer predisposition (Coccia, Ruggiero et al. 2007; Burroughs, Woolfrey et al.
2009). The most common hematological abnormality among SDS patients is neutropenia
(88-100% of patients), however, other hematological manifestations have been observed.
These include anemia, thrombocytopenia, and pancytopenia, with anemia being the
second most common cytopenia observed in SDS patients (Smith, Hann et al. 1996). In
addition to bone marrow failure, retrospective studies of SDS patients reveal a high
propensity for malignant transformation to myelodysplastic syndrome (MDS) and acute
myeloid leukemia (Alter 2007; Coccia, Ruggiero et al. 2007).
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Exocrine pancreatic dysfunction is considered one of the hallmark clinical
features of SDS and is an essential component of its diagnosis. Histological analyses of
pancreases from SDS patients reveal a scarcity of pancreatic acinar cells replaced by fatty
deposits within the gland causing a reduction/absence of trypsin, lipase, and amylase in
pancreatic fluid (Shimamura 2006). As a result, SDS patients with exocrine pancreatic
insufficiency generally suffer from malabsorption of nutrients and steatorrhea with
symptoms typically becoming evident within the first 6 months of life.

Pancreatic

function in SDS patients has been reported to improve with age (Hall, Dale et al. 2006).
In addition to these characteristic hematological abnormalities and pancreatic
dysfunction, other clinical features in SDS include genitourinary tract irregularities,
cardiac defects, and intellectual difficulties (Aggett, Cavanagh et al. 1980; Savilahti and
Rapola 1984; Kent, Murphy et al. 1990).

SDS Genetics: Gene Conversions and Disruptions in Coding Potential
Shwachman-Diamond syndrome has an autosomal-recessive mode of inheritance.
In 2002, pathogenic mutations in the SBDS (Shwachman-Bodian-Diamond
Syndrome) gene were shown to be responsible for the disease (Boocock, Morrison et al.
2003). This highly conserved gene, which maps to chromosome 7q11, spans a region of
7.9 kb and is composed of five exons. Distally located to the SBDS locus is a paralogous
pseudo gene (SBDSP) whose transcript shares 97% identity with SBDS and contains
numerous inactivating mutations. The high degree of sequence similarity among SBDS
and SBDSP may explain why most of the mutated alleles associated with SDS
(approximately 75%) are the result of gene conversion events between SBDS and its
adjacent pseudogene (Boocock, Morrison et al. 2003).
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Coding region alterations

identified in affected individuals with SDS include mIssense and frameshift
modifications.

The most common mutations among SDS patients are the truncating

SBDS mutations, 183-184

TA~CT

and

258+2T~C

(both gene conversion events).

which result from the introduction of an in-frame stop codon or the mutation of a donor
splice site which causes a concomitant frame shift, respectively (Boocock, Morrison et al.
2003). Both of these mutations result in severely truncated Sbds proteins. Most SDS
patients are compound heterozygotes.

Several harbor the 183-184

TA~CT

and

258+2T ~C biallelic mutations with a large majority (about 89%) of patients having at
least one of these early truncating SBDS mutations (Boocock, Morrison et al. 2003). No
patient is homozygous for the 183-184

TA~CT

mutant allele, suggesting that patients

are likely hypomorphs deriving small amounts of functional protein from the splice site
allele. This observation is supported by a mouse model for SDS where it was shown that
a complete loss of SBDS (Sbds- I -) results in embryonic lethality (Zhang, Shi et al. 2006).

In the same study, Sbds +1- heterozygous mice lacked an observable phenotype that was
distinct from wild-type littermates. These reports suggest the molecular pathogenesis and
related clinical features of SDS are the consequence of residual expression from mutated
SBDS alleles.

SBDS Protein: The Structure and Proposed Function

The SBDS locus encodes a polypeptide of 250 amino acids whose function is
largely unknown. The SBDS mRNA and protein are broadly expressed throughout many
human tissues at both the message and protein levels (Boocock, Morrison et al. 2003;
Woloszynek, Rothbaum et al. 2004; Burroughs, Woolfrey et al. 2009). The Sbds protein
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is present in both the cytoplasm and the nucleus of cells, but is particularly concentrated
within the nucleolus (Woloszynek, Rothbaum et al. 2004; Austin, Leary et al. 2005).
SBDS is a highly evolutionarily conserved protein with putative orthologues present in
archaeal and eukaryotic kingdoms.

No orthologue has been identified in eubacteria

(Savchenko, Krogan et al. 2005). The only known structural information concerning
SBDS is based on X-ray structures of the archaeal orthologues from Archaeoglobus
fulgidus

(afSBDS)

and

Methanothermobacter

thermautotrophicus

(mthSBDS)

(Savchenko, Krogan et al. 2005; Shammas, Menne et al. 2005; Ng, Waterman et al.
2009). These X-ray studies reveal the SBDS protein possesses a tripartite structure with
three characteristic domains consisting of a novel N-terminal FYSH domain (fungal,
YHR087Wp, Shwachman), a common three-helical bundle domain, and a C-terminal
domain possessing a ferredoxin-like fold (Figure 3).
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II

Figure 3.

Ribbon diagram modeled after the crystal structure of the

Methanothermobacter thermautotrophicus SBDS protein (mthSBDS).

Ribbon is

constructed with colors that merge from the color blue (N-terminus) to red (C-terminus).
Protein folding domains are labeled I (residues 1-88), II (residues 89-162), and III
(residues 163-232) and correspond to the N-terminal FYSH domain, three-helical bundle
domain, and C-terminal ferredoxin-like fold containing domain, respectively.
adapted from Ng, Waterman et al. 2009.
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Image

The X-ray crystallographic structure of SBDS bares no obvious homology to
common protein functional domains and thus function is difficult to infer based on
structural characteristics alone. It is noteworthy that the novel N-terminal FYSH domain
of the human SBDS protein is often the target of disease related mutations in
Shwachman-Diamond syndrome and that it also possesses the highest sequence
conservation among the archaeal and eukaryotic SBDS proteins (Boocock, Morrison et
al. 2003; Nicolis, Bonizzato et al. 2005; Boocock, Marit et al. 2006). The N-terminal
FYSH domain shares some sequence similarity to another yeast protein (YHR087Wp)
that has genetic interactions with proteins involved in rRNA processing (Savchenko,
Krogan et al. 2005). These observations suggested that the N-terminal FYSH domain of
the SBDS protein was likely important for its function and that this function may involve
pathways involved in RNA metabolism or ribosome biogenesis.
Initial reports, based largely on studies in archaebacteria and yeast, also hinted at
a role for the SBDS family of proteins in RNA metabolism. For example, SBDS was
shown to reside within a predicted superoperon encoding components of the exosome, a
complex of RNases and RNA-binding proteins involved in numerous RNA processing
reactions (Koonin, Wolf et al. 2001).

Also, micro array expression studies in yeast

demonstrated that the SBDS yeast ortholog, SDO 1 (YLR022C), is regulated in a
coordinate fashion with genes encoding proteins involved in RNA processing and
ribosome maturation (Wu, Hughes et al. 2002; Peng, Robinson et al. 2003). Congruent
with these previous results, affinity purification of TAP tagged Sdo 1 in yeast
demonstrated a number of physical interactions with proteins involved in rRNA
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processing, as well as with protein components of the 60S ribosomal subunit (Savchenko,
Krogan et al. 2005).

The Molecular Pathogenesis of SDS Remains Elusive
Early studies pointed to an intrinsic defect in hematopoietic stem cells as the
underlying cause of bone marrow failure in SDS patients. These studies demonstrated
defective proliferative potential and diminished numbers of committed myeloid
progenitors in the marrow of SDS patients, underscored by a paucity of granulocytemonocyte colony-forming units (CFU-GM) and erythrocyte burst-forming units (BFU-E)
(Saunders, Gall et al. 1979; Woods, Krivit et al. 1981; Suda, Mizoguchi et al. 1982).
Almost two decades later, Dror and Freedman demonstrated that SDS patient derived
bone marrow aspirates contained marked reductions in the quantity of CD34+
hematopoietic progenitors in comparison to normal individuals; they also showed SDS
patient derived CD34+ cells to possess a reduced proliferative capacity discernible by
diminished progenitor colony development and impaired long-term colony formation.
Finally, they were able to show that stromal cells derived from SDS marrow exhibit an
impaired ability to support normal CD34+ cells in long-term colony formation assays
(Dror and Freedman 1999). These data suggest an inherent stem-cell defect together with
an aberrant bone marrow stroma or defective hematopoietic microenvironment as
contributing factors in SDS associated marrow dysfunction.

Increased apoptosis is

implicated as a central pathogenic mechanism in SDS. Both accelerated apoptosis and
enhanced expression of the p53 tumor suppressor protein have been reported in bone
marrow derived from SDS patients. These observations provide a potential explanation
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for the decreased numbers of CD34+ cells in SDS patients and their reduced ability to
form hematopoietic colonies (Dror and Freedman 2001; Eighetany and Alter 2002;
Rujk:ijyanont, Watanabe et al. 2008).
In vitro and in vivo animal studies have demonstrates that SBDS is essential for

hematopoiesis and pancreatic development. Morpholino-mediated knockdown of Sbds in
zebrafish results in aberrant exocrine pancreas morphogenesis and abnormal granulocyte
development and distribution within embryos (Venkatasubramani and Mayer 2008).
Further, lentiviral-mediated RNAi knockdown of Sbds in murine hematopoietic
progenitor cells lead to defective granulocytic differentiation in vitro and impair both
short-term hematopoietic engraftment and homing of hematopoietic progenitors to bone
marrow following in vivo transplantation (Rawls, Gregory et al. 2007). In addition to
these studies recapitulating some of the human pathologic characteristics associated with
SDS, they also, in part, support additional roles for SBDS in chemotaxis and/or cell
motility (Stepanovic, Wessels et al. 2004; Wessels, Srikantha et al. 2006; Orelio and
Kuijpers 2009). This view is substantiated by numerous studies, which demonstrate SDS
patient-derived neutrophils have chemotactic and mobility abnormalities (Aggett, Harries
et al. 1979; Aggett, Cavanagh et al. 1980; Ruutu, Savilahti et al. 1984; Repo, Savilahti et
al. 1987; Dror, Ginzberg et al. 2001).
Many studies suggest that members of the SBDS family of proteins function in
ribosome synthesis.

Consistent with this view, SBDS has been shown to reside

predominantly within the nucleolus (Austin, Leary et al. 2005). Human cell studies have
also shown that SBDS co-sediments with 60S ribosomal subunits in sucrose gradients,
but not with mature subunits actively participating in translation. This association was
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confirmed by SBDS co-precipitatation with 28S rRNA, an RNA component of 60S
ribosomal subunits (Ganapathi, Austin et al. 2007).

Ganapathi and colleagues

(Ganapathi, Austin et al. 2007) also demonstrated that SDS patient derived cells have a
hypersensitivity to low doses of the rRNA transcription inhibitor, actinomycin D,
indicative of defective ribosome assembly. In these reports, the loss of SBDS was not
associated with any discrete rRNA processing defects or with quantitative decreases in
60S ribosomal subunits (Ganapathi, Austin et al. 2007). Contrary to these earlier reports,
later studies reveal cells derived from an SDS mouse model exhibit a diminution in large
ribosomal subunits (Ball, Zhang et al. 2009).

Proteomic analyses of SBDS binding

partners show that it is complexed with nucleophosmin (NPM), a multifunctional
nucleolar protein connected to both ribosome biogenesis and oncogenesis (Okuwaki,
Tsujimoto et al. 2002; Grisendi, Mecucci et al. 2006; Ganapathi, Austin et al. 2007). In
addition, both yeast two-hybrid and GST pull-down assays revealed SBDS associates
with Nip7, a conserved large ribosomal subunit associated protein involved in the
terminal steps of 60S subunit maturation (Zanchin, Roberts et al. 1997; Hesling, Oliveira
et al. 2007). Further studies in HEK293 cells failed to demonstrate any effects of SBDS
depletion on ribosome biogenesis, however, rRNA processing defects were evident
(Hesling, Oliveira et al. 2007). These studies also showed that depletion of SBDS leads
to alterations in both mRNA message abundance and translational efficiency of vital
genes involved in blood cell differentiation and proliferation, bone morphogenesis, and
nervous system development (Hesling, Oliveira et al. 2007).
As previously noted, studies on the yeast SDO 1 gene reveal a role for this protein
in 60S subunit maturation.

Menne and colleagues proposed that Sdo 1 functions to
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promote the dissociation and concomitant recycling of anti-association factor Tif6 from
nascent 60S subunits in the cytoplasm to the nucleolus (Menne, Goyenechea et al. 2007).
Yeast Tif6, the ortholog of mammalian eIF6, is an essential protein that is required for
60S subunit maturation and nuclear export (Basu, Si et al. 200 I; Ceci, Gaviraghi et al.
2003). Further, in vitro studies show that Tif6 functions as a subunit anti-association
factor that prevents 60S subunits from prematurely associating with 40S subunits prior to
appropriate initiation complex formation (Si and Maitra 1999). Interestingly, mutations
in Tif6 rescue the slow growth phenotype associated with the complete loss of Sdo 1
(Menne, Goyenechea et al. 2007).

To date, mutations in TIF6 that rescue the slow

growth phenotype of SDOI mutants, map to a single surface of Tif6, which presumably
mediates its interaction with 60S ribosomal subunits. These mutations are thought to
reduce the affinity of Tif6 for 60S subunits. Based on these observations, it is proposed
that Sdo 1 functions to release Tif6 from subunits once they reach the cytoplasm. Sdo 1
may not, however, function alone in facilitating the release of Tif6 from 60S subunits.
Mutations in EFLI, a yeast gene encoding a cytoplasmic GTPase, which shares
homology to elongation factor EF-GIEF-2, give rise to phenotypes similar to loss-offunction mutations in TIF6. Mutations in both genes result in a severe slow growth
phenotype underscored by comparable pre-rRNA processing defects, 60S subunit
deficits, and impaired 60S subunit nuclear export (Basu, Si et al. 2001; Senger,
Lafontaine et al. 2001). In vitro studies show that Efll functions to dissociate Tif6 from
60S subunits, and intriguingly, mutations in TIF6 suppress phenotypes associated with
EFLI mutations (Senger, Lafontaine et al. 2001).

Thus, genetic analysis clearly

demonstrates an epistatic relationship between SDOI and EFLI, and suggests that both
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proteins function together to promote the dissociation of Tif6 from 60S ribosomal
subunits. Once released, Tif6 can be recycled back to the nucleolus where it participates
in additional rounds of 60S subunit maturation (Menne, Goyenechea et al. 2007). Recent
data from Zhang and colleagues indicate reduced amounts of 60S subunits in embryonic
fibroblasts derived from an SDS mouse model suggesting that the mammalian Sbds
protein may have a similar role in 60S subunit biogenesis (Ball, Zhang et al. 2009).
Collectively, these studies home in on potential cellular processes and pathways
that could potentially bridge the gap between aberrations in ribosome synthesis and SDS
related marrow dysfunction. The specific molecular mechanisms relating SDS associated
defects in ribosome biogenesis to the heterogeneous phenotype observed in SDS patients
remain to be explained, as do those mechanisms that make SDS pathologically distinct
from other bone marrow failure disorders whose molecular bases are also linked to
defects in ribosome biogenesis, such as DBA.

Dissertation Overview
Overall Goal

The work presented in this dissertation is focused on in vivo models of
Shwachman-Diamond syndrome and Diamond-Blackfan anemia. Here I made use of
yeast models for both diseases, each targeting the 60S ribosomal subunit. The overall
goal was to explore the molecular mechanisms by which the maturation of 60S subunits
was affected in both disease models.

Further, concerning the yeast SDS model, the

objective was to analyze the function of Sdol in 60S subunit maturation from the
perspective of its potential role as a regulator of protein acetylation. Investigation of
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these disease models may reveal commonalities and/or differences among their
underlying molecular defects, potentially leading to the elucidation of umque
mechanisms and/or signaling pathways that could explain their inimitable clinical
manifestations, as well as potentially lead to the identification of prospective therapeutic
targets.

Hypothesis and Research Aims
I hypothesized that both DBA and SDS yeast models would result in a deficit in
functional 60S ribosomal subunits, though by divergent mechanisms.

In aim I, I

demonstrated distinct ribosome maturations defects among yeast models of DBA and
SDS. With the discovery that histone deacetylase inhibitors partially reverse the growth
defect of the yeast SDS model, in aim II, I focused on the role of acetylation in ribosome
maturation and its implications for SDS pathophysiology and treatment.
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CHAPTER II
DISTINCT RIBOSOME MATURATION DEFECTS IN YEAST MODELS OF
DIAMOND-BLACKFAN ANEMIA AND SHWACHMAN-DIAMOND SYNDROME

Introduction

As previously noted, both DBA and SDS are congenital bone marrow failure
syndromes linked to defects in ribosome synthesis and/or function (Liu and Ellis 2006).
They are also characterized by a heterogeneous collection of congenital anomalies and a
predisposition to cancer. Although both diseases share these general features, there are
substantial differences in their clinical manifestations. DBA is characterized by a red
blood cell hypoplasia, whereas SDS is frequently characterized by neutropenia, although
other hematopoietic lineages may also be affected in both disorders. Patients with SDS
also display exocrine pancreatic deficiency, which is not observed in DBA (Hall, Dale et
al. 2006). The congenital anomalies in SDS include short stature, skeletal defects, and
neurological problems. Patients with DBA also have short stature, but in contrast to
SDS, craniofacial anomalies are the most commonly associated congenital malformations
along with other abnormalities, including triphalangeal thumbs and genitourinary tract,
and cardiac defects (Freedman 2000; Lipton, Atsidaftos et al. 2006). Both diseases carry
an increased risk of cancer, but differ in neoplastic potential and associated types of
malignancies.

Approximately 30-40% of SDS patients progress to develop

myelodysplastic syndrome and/or acute myelogenous leukemia. The incidence of cancer
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in DBA patients is lower, approximately 2%. Both solid tumors and blood-based cancers
have been observed in patients with DBA (Lipton, Atsidaftos et al. 2006).
The molecular underpinnings of both DBA and SDS converge on a common
target, the ribosome.

To date, the genes involved in DBA all encode structural

components of the ribosome. Three of these genes, RPS17, RPS19, and RPS24 encode
ribosomal proteins of the 40S subunit (Draptchinskaia, Gustavsson et al. 1999; Gazda,
Grabowska et al. 2006; Cmejla, Cmejlova et al. 2007). More recently, RPL5, RPLll, and
RPL35A genes encoding 60S subunit ribosomal proteins have also been shown to harbor
pathogenic mutations in DBA (Farrar, Nater et al. 2008; Gazda, Sheen et al. 2008).
Several studies show that ribosomal proteins affected in DBA are required for the
maturation of ribosomal subunits indicating that the basis for the clinical features of DBA
resides in abortive ribosome synthesis (Choesmel, Bacqueville et al. 2007; Flygare,
Aspesi et al. 2007; Idol, Robledo et al. 2007; Farrar, Nater et al. 2008; Gazda, Sheen et al.
2008). In SDS, the gene affected is SBDS, which encodes a protein associated with 60S
ribosomal subunits (Ganapathi, Austin et al. 2007). SBDS is not a structural component
of the ribosome. The yeast ortholog of SBDS, Sdo 1, has been reported to be required for
the biogenesis and function of the 60S ribosomal subunit (Menne, Goyenechea et al.
2007). In contrast, there have been conflicting reports regarding the role of SBDS in the
biogenesis of 60S ribosomal subunits in mammalian cells (Ganapathi, Austin et al. 2007).
While these data indicate that both DBA and SDS may arise through defects in ribosome
synthesis and/or function, little is known about how these changes in this common target
result in the distinct clinical presentations of the two diseases.
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Studies in animal models of DBA have recently shown that the tumor suppressor
p53 plays an important role in developmental and hematologic phenotypes (Danilova,
Sakamoto et al. 2008; McGowan, Li et al. 2008; Uechi, Nakajima et al. 2008). These
findings are generally interpreted in the context of a model in which some form of
nucleolar stress signaling promotes p53 stabilization and activation (Pestov, Strezoska et
al. 2001). Two pathways appear ideally suited to link features of abortive ribosome
assembly to growth control and apoptosis. Both involve MDM2, a zing-finger ubiquitin
ligase, which targets p53 for proteasomal degradation. Several ribosomal proteins bind to
MDM2 and inhibit its ubiquitin ligase activity resulting in p53 stabilization and activation
(Lindstrom, Deisenroth et al. 2007). In this model, ribosomal proteins are liberated from
productive assembly into ribosomal subunits and are free for signaling through MDM2.
Alternatively, nucleolar stress can also signal through the ARF tumor suppressor (Gjerset
2006).

This latter pathway appears to involve nucleophosmin, a nucleolar protein

recently shown to be involved in ribosome trafficking from the nucleus to the cytoplasm
(Maggi, Kuchenruether et al. 2008).
The recent discoveries of genes encoding 60S subunit ribosomal proteins mutated
in DBA allowed me to focus on the large ribosomal subunit as a common target in yeast
models for DBA and SDS (Farrar, Nater et al. 2008; Gazda, Sheen et al. 2008). These
models employed yeast strains mutated in RPL33A, the yeast ortholog of RPL35A
mutated in DBA (Freedman 2000), and SD01, the ortholog of SBDS mutated in SDS
(Boocock, Morrison et al. 2003). The overall goal was to determine whether there are
molecular features that differentiate the two disease models.

Here I show that both

models affect the production of 60S subunits, but do so by distinct biochemical
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mechanisms which affect different stages of the subunit maturation pathway.

The

subunit deficit in the DBA model is linked to an assembly defect that results in immature
particles that are rapidly degraded. This assembly defect is associated with a substantial
increase in the amount of extra-ribosomal 5S ribosomal RNA (rRNA). This observation
is intriguing in light of the observation that, in mammalian cells, ribosomal proteins Rpl5
and Rp111, in complex with 5S rRNA, interact with MDM2 and promote p53
stabilization and activation (Hom and Vousden 2008). In contrast to the data obtained
for the DBA model, the subunit deficit in the SDS model is linked to defects later in the
subunit maturation pathway. As a consequence of this rather late maturation defect, a
significant fraction of the 60S subunit precursors found in the SDS model are retained
within the nucleoplasm associated with 5S rRNA. Thus, the two disease models differ
dramatically in terms of their effects on subunit assembly and the potential for
subsequent diversion of ribosomal components from their normal assembly pathway to
potential interactions with other growth regulatory factors within cells. These models,
therefore, provide a mechanistic basis for how differing effects on 60S subunit
maturation could potentially trigger alternative signaling pathways within cells that give
rise to the distinct clinical phenotypes of DBA and SDS.

Design and Methods

Yeast Strains
The yeast strains used in these studies were generated by the Saccharomyces
genome deletion project and were obtained from either Research Genetics or Euroscarf.
Heterozygous diploids for SDOI (20519D: MAT ala ura3-lIura3-1, his3-11lhis3-11,
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leu2-3_112lleu2-3_112,

trplL12ItrplL12,

ade2-1Iade2-1,

canl-lOO/canl-lOO,

sdol::kanMX4ISDOl) and RPL33A (22109: MAT ala his3LJlI his3L11, leu2LJ0lleu2LJ0,
lys2L101+, met15LJOI+, ura3LJ0lura3LJ0, rpl33A::kanMX4IRPL33A) were sporulated and

resulting haploid strains were employed. Because the genetic background of the SDO 1
mutant was W303 and the RPL33A strain was BY4743, the RPL33A disruption was
backcrossed into the W303 background for the experiments reported here. The genotype
of the RPL33A strain used was MAT ala ura3-1Iura3-1, his3-11lhis3-11, leu2trpLJ2ItrplL12,
rpI33A::kanMX4IRPL33A.

ade2-1Iade2-1,

canl-l OO/canl-l 00,

Because of a high spontaneous suppression rate of both

SDOI and RPL33A mutants, haploid strains were freshly derived for each experiment.

Polysome profiling, northern hybridization, and pulse-chase analyses
Cell extracts were prepared for polysome analysis as previously described (LegerSilvestre, Caffrey et al. 2005). Yeast strains were inoculated into 100 ml of glucose rich
media (YPD) and were allowed to grow to mid-log phase at 30°C. At this time, 5 mg of
cycloheximide was added to flasks containing cells and media, swirled, and poured into
chilled nalgene® centrifuge bottles. Cells were harvested at 5,000 RPM (-3,000 x g) for
10 minutes. Following centrifugation, the supernatant was decanted, and cell pellets
were resuspended in 5 ml of polysome buffer (10 mM Tris-HCI [pH 7.5], 100 mM NaCI,
30 mM MgCh, 50 !-Ig/ml cycloheximide, 100 !-Ig/ml heparin, 0.2 !-Il/ml DEPC). Cell
suspensions were then transferred to 12 ml pop-top tubes, centrifuged again, and the
washing step repeated with polysome buffer. Cell pellets were resuspended in 1 ml of
polysome buffer and 0.30 grams of 425-600 micron glass beads were added. Cell/glass
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bead suspensions were then mechanically lysed by vortexing at high speed, 8 times, 15
seconds each, with 30 second cool down periods between bursts. Following cell lysis,
1.5 ml of polysome buffer was added and extracts centrifuged at 5,000 x g at 4°C for 5
minutes to remove unbroken cells and debris. Supernatants were decanted into new 12
ml pop-top tubes, centrifuged again at 10,000 x g for 5 minutes, and supernatants saved.
Polysome extracts (1 ml of 1:100 A260 - 0.15) were loaded onto 7-47% stepwise sucrose
gradients and centrifuged at 28,000 rpm for 6 hours in an SW28.1 rotor (Beckman
Instruments, Inc., Fullerton, CA, USA).

Sucrose gradients were fractionated and the

absorbance at 254 nm monitored using an ISCO model 185 gradient fractionator
interfaced to a UA-6 absorbance detector (Teledyne Isco, Inc., Lincoln, NE, USA).
RNA was recovered from sucrose gradient fractions after precipitation with 2
volumes of absolute ethanol. Precipitates were collected by centrifugation for 10 min at
1O,000xg and then suspended in 0.3 mL of 20 mM Tris-HCI pH 7.4, 2.5 mM EDTA, 100
mM NaCl, and 1% sodium dodecyl sulfate.

Suspensions were extracted twice with

phenol/Chloroform and RNA in the aqueous phase was precipitated overnight at -20°C
with 2.5 volumes of ethanol. RNA was collected by centrifugation, washed once with
70% ethanol, dried in vacuo, and suspended in DEPC-treated water. RNA was resolved
on 1.5% formaldehyde-agarose gels, transferred to Zeta-Probe (Bio-Rad Laboratories,
Hercules, CA, USA), and hybridized with oligonucleotides labeled at their 5' ends with
32[p]. Oligonucleotides were radio-labeled using polynucleotide kinase and 1-32[p]_ATP.
The

oligonucleotides

were:

employed

CAGTTGATCGGACGGGAACA-3',

5.8S
and

CGTATCGCATTTCGCTGCGTTC-3',
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5S

rRNA

probe
probe
probe

5'5'5'-

GGCCAGCAATTTCAAGTTA-3'.

The procedures for pulse-chase analysis are

described elsewhere (Leger-Silvestre, Caffrey et al. 2005).

Data were scanned and

digitized using Adobe Photoshop.

Live cell fluorescence imaging
Yeast strains were transformed with PRS316-RPL25eGFP (URA3) and pUN 100DsRed-NOPl (LEU2) vectors using an Alkali-Cation™ Yeast Kit (Qbiogene, Inc.,
Carlsbad, CA, USA) as directed by the manufacturer. Isolated transformants were grown
to mid-log phase in synthetic complete liquid media lacking leucine and uracil. One
milliliter aliquots were centrifuged at 10,000 RPM

(~9,000

x g) for 15 s to pellet the

cells. The supernatant was discarded and the resulting pellet was washed with 0.5 mL of
KPOJsorbitol wash solution (I.2M sorbitol, O.IM potassium phosphate, pH 7.5). Cell
pellets were re-suspended in 300 fAL of KPOJsorbitol wash solution and 1 fAl of 10 fAg/ml
4',6-diamidino-2-phenylindole (DAPI) nuclear stain added. CelllDAPI suspensions were
incubated at room temperature for 10 min, washed twice with KPOJsorbitol solution, resuspended in 200 fAL of KPOJsorbitol, and 2.5 fAL of this cell suspension placed on glass
microscope slides. Cells were subjected to fluorescent imaging using a Zeiss Axiovert
200 multi-channel fluorescence microscope (Carl Zeiss MicroImaging, Inc., Thornwood,
NY, USA).
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Results

Yeast strains heterozygous for RPL33A and SDO 1 deletions were obtained from
Euroscarf or Research Genetics. The diploid strains were sporulated, tetrads dissected,
and resulting haploid progeny grown on rich media. Compared with wild-type cells, cells
harboring either deletion had a pronounced growth deficit (Figure 4). To assess the effect
of the RPL33A and SDOl deletions on the steady-state level of 60S subunits, extracts
were prepared in a magnesium free buffer in which polysomes and 80S monosomes
dissociate completely into 40S and 60S ribosomal subunits. The ratio of 60S to 40S
subunits was used to examine the selective effect of these mutations on 60S subunit
levels beyond any overall reduction in ribosome synthesis linked to reduced growth rate.
Figure 5 illustrates that both yeast strains exhibit a reduction in the quantity of 60S
subunits relative to 40S subunits when compared to wild-type cells.

The relative

reduction of 60S subunits in the two mutant strains differed by approximately 10% with
the I1RPL33A showing the greater overall reduction.
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A

B
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Wild-type

Wild-type

llRPL33A

IlSD01

Wild-type

IlSD01

llRPL33A

Wild-type

Figure 4. Haploid yeast strains possessing deletions in RPL33A or SDOl have a

pronounced growth defect. (A) ARPL33A and (B) !1SDOl heterozygous diploid strains
were sporulated, their tetrads dissected and resultant haploid progeny grown on glucose
rich media.

Photographic images containing four haploid daughter cells from one

dissected tetrad are shown and are accompanied by a schematic diagram representing
colony size with corresponding genotypes labeled.
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Figure 5. Yeast models of DBA and SDS both exhibit deficits in the relative amount

of 60S to 40S ribosomal subunits. Extracts for subunit analysis were prepared as
described for polysome isolation except magnesium was omitted from the buffers.
Ribosomal subunits were resolved on 7-47% stepwise sucrose gradients via
centrifugation. Gradients were fractionated and the absorbance at 254 nm monitored
using a gradient fractionator interfaced to a UA-6 absorbance detector.

Ribosomal

subunits were quantified by determining the area under the curve (peak integration) in
resultant absorbance tracings. The bar graph reports the ratio of 60S to 40S in wild-type,
!1SDO 1, and MPL33A strains. Error bars corresponding to the standard error of the

mean (SEM) are shown. Statistical significance was assessed by Student's t test. tWildtype strain versus mutant strains (p<O.OOOl).
(p<O.02).
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*!1SDOl

strain versus !1RPL33A strain

I used pulse-chase analysis of pre-rRNA processmg for a more detailed
characterization of subunit maturation in the DBA and SDS disease models. The yeast
pre-rRNA processing pathway is shown in Figure 6A. Relative to the wild-type strain,
the RPL33A mutant shows a pronounced delay in the production of mature 25S rRNA
such that by 10 min of chase the amount of radio-label in 25S rRNA relative to I8S
rRNA is significantly less than the approximate 2: 1 ratio observed in wild-type cells
(Figure 6B top panel). This selective effect on 25S rRNA synthesis is accompanied by
delayed maturation of several pre-rRNA precursors including 35S, 23S, and 27S prerRNA. The delayed maturation of 35S and 23S pre-rRNA is the result of an ill-defined
feedback system in which early steps in pre-rRNA processing are slowed in mutants that
affect the maturation of 60S subunits (Venema and Tollervey 1999).

The delayed

maturation of 27S pre-rRNA species, on the other hand, accounts for the selective effect
of the MPL33A mutant on the maturation of 60S subunits. The top panel of Figure 6B
shows a 27S pre-rRNA doublet that persists through the lO-min chase period.

This

doublet consists of 27S A z/A 3 species (upper band) and I7S B (lower band). The primary
effect of the RPL33A deletion is a delay in maturation of 27S A2/A3 pre-rRNA as
evidenced by the increased ratio of 27S A21A3 to 27S B pre-rRNA observed by northern
analysis (Figure 6C). The data from the !1SDOl strain, on the other hand, revealed a
more complex effect on 60S subunit maturation. As for the MPL33A strain, there was a
delay in 35S and 23S pre-rRNA processing, consistent with the feedback effect of a
reduction in 60S subunits on early steps in pre-rRNA processing. The persistence of 35S
and 23S pre-rRNA in the !1SDOl strain indicates that cleavage steps Ao and Al involved
in the maturation of the 5' end of 18S rRNA may be more adversely affected when
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compared with the MPL33A strain. Moreover, there was clearly a delay in 27S B prerRNA processing apparent by pulse-chase analysis in the I1SDOl mutant relative to wildtype cells (Figure 6B, bottom panel); this delay could also be observed by northern
analysis (Figure 6C). Surprisingly, however, the effect of this delay on the production of
25S rRNA did not appear to be as great as that observed in the MPL33A strain since the
ratio of 25S to I8S rRNA in this strain was still greater than one.
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Figure 6.

Yeast models of DBA and SDS display discrete pre-rRNA processing

defects. (A) The major pre-rRNA processing pathways in S. cerevisiae. Mature rRNA
species are res presented by boxes. External and internal transcribed sequences are shown
as thin lines. Numbered letters indicate processing sites. Horizontal arrows represent
exonucleolytic cleavages; other cleavage steps are endonucleolytic.

An alternative

pathway (not shown) has cleavage at site A2 preceding cleavages at sites Ao and AI
giving rise to 23S pre-rRNA. (B) Pulse-chase analysis of pre-rRNA processing in yeast
models of DBA and SDS. Top panel, MPL33A strain (Mut) and isogenic wild-type
(Wt); bottom panel, I1SDOl strain (Mut) and isogenic wild-type (Wt). Cells were pulselabeled for 2 min with [methyl-3H]-methionine and chased in the presence of 1 mg/mL
methionine for the indicated times. Total RNA was prepared and fractionated as outlined
in the Design and Methods section. Mature and pre-rRNA species are labeled to the left
of each panel. Schematic diagrams to the right correlate to each of the rRNA processing
intermediates noted to the left. RNAs showing delayed processing relative to wild-type
are marked with an asterisk. (C) Northern blot analysis of pre-rRNA processing in yeast
models of DBA and SDS. Total RNA was prepared and resolved as outlined in the
Design and Methods section. A radiolabeled oligonucleotide probe that hybridizes to the
C2 processing site located within internal transcribed spacer 2 (ITS2) was used for
northern analyses. Membranes were exposed to BioMax MS film at -800 C using a
BioMax LE intensifying screen and then subjected to phosphorimage analysis.
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A more comprehensive analysis of the protein synthetic apparatus in the two
disease models was based on polysome profiles. Polysome profiles from the I1RPL33A
strain showed a marked reduction in free 60S subunits relative to wild-type and the
appearance of half-mer polysomes (Figure 7, middle panel). Half-mer polysomes are
polysomes with stalled 48S initiation complexes and are a common characteristic of yeast
strains with a deficit of 60S subunits (Rotenberg, Moritz et al. 1988). The polysome
profiles from the I1SDOl strain also exhibited half-mer polysomes, but in contrast to the

MPL33A strain, there was a significant pool of free 60S subunits and a noteworthy
decrease in mean polysome size (Figure 7, bottome panel).

These data differ from

previously reported polysome data from SDO 1 mutants when neither half-mer polysomes
nor a free pool of 60S subunits was observed (Menne, Goyenechea et al. 2007). Both
mutant strains show a peak to the left of the 40S peak which is absent in the wild-type
strain. This peak contains 20S RNA, an endogenous virus-like particle (termed the 20S
replicon) induced by various forms of translational stress (Wickner 1996).
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Wild-Type

Polysomes
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~Rp133A

.,t
e

~Sdo1

!,t
Figure 7. Polysome profiles from yeast models of DBA and SDS differ in the amount

of free 60S subunits. Top panel, wild-type; middle panel, !:!'RPL33A; bottom panel,
!:!'SDO 1.

Cell extracts were prepared and fractionated as outlined in the Design and

Methods section.

Subunit peaks were identified by analyzing the rRNA species co-

sedimenting with each peak. The left hand side of each panel represents the top of the
sucrose gradient. The schematic diagrams to the right of the mutant profiles indicate that
half-mer polysomes arise as a consequence of a 60S subunit deficit in the MPL33A
strain whereas in the !:!'SDO 1 strain 60S subunits are present but unable to engage in
translation. Polysome analysis was performed in triplicate for each strain. The profile
shown is representative.
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To evaluate the intracellular distribution of 60S subunits in the two disease
models, 60S subunits were tracked using a GFP-RpI25 fusion protein. Several studies
have shown that this protein is assembled into 60S subunits and can be used to monitor
the distribution of such subunits within cells. In wild-type cells GFP fluorescence was
distributed throughout nuclear and cytoplasmic regions but was reduced in intensity in
the region corresponding to resident vacuoles (Figure 8, top panel). In I'1RPL33A cells,
cytoplasmic GFP fluorescence intensity was diminished, with discrete regions of
enhanced GFP fluorescence that coincided with Nop! and DAPI staining (Figure 8,
middle panel). Rp133, like many yeast ribosomal proteins, is encoded by duplicated
genes that are nearly identical. Therefore, the cytoplasmic staining within these cells
presumably results from the incorporation of Rp133B into 60S subunits. The nucleolar
localized GFP fluorescence observed in the I'1RPL33A strain likely represents the modest
accumulation of immature 60S subunits as a consequence of delayed pre-rRNA
processing at sites A2 and A 3.

The overall reduction in GFP-RpI25 staining in the

I'1RPL33A strain relative to wild-type indicates that these immature precursors are subject

to enhanced decay. In contrast, I'1SDO J strains showed a pronounced accumulation of
fluorescence in regions that broadly encompass Nopl and DAPI staining and likely
represent the retention of more fully matured 60S subunits in the nucleoplasm (Figure 8,
bottom panel).

Given the relative reduction of 60S subunits in the I'1SDOJ strain

observed from the subunit profiles in Figure 5, I believe a fraction of these more fully
matured subunits accumulating in the absence of Sdo 1 undergo degradation, albeit at a
much slower rate than that observed for immature subunits in the MPL33A strain.
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Figure 8, Nuclear retention of pre-60S subunits in the yeast SDS model. Live cell
fluorescence images corresponding to wild-type (top row), MPL33A (middle row), and
/!o:,.SDOl (bottom row) strains.

Wild-type and mutant strains were transformed with

Rp125-GFP (a component of 60S ribosomal subunits) and Nopl-DSred (nucleolar
protein). Left column, Rp125-GFP fluorescence; middle left column, Nopl-RFP; middle
right column, DAPI stain; right column, merge of all three images. Images depicted were
chosen to be accurate representations of a collection of fluorescence studies performed in
triplicate.
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Collectively, these data indicate that the defect in 60S subunit maturation between the
two disease models occurs at a later step in the I'1SDO 1 strain than in the I'1RPL33A strain,
resulting in the accumulation of more fully matured precursors in the former relative to
the latter.
Based on the emerging role for the SS rRNA subcomplex in signaling abortive
ribosome assembly to pS3 activation in mammalian cells, I examined the fate of SS
rRNA in the yeast models of DBA and SDS. In wild-type cells, SS rRNA is found in
fractions corresponding to 60S subunits, 80S monosomes, and polysomes, with only a
small fraction of extra-ribosomal SS rRNA found near the top of the gradient (Figure 9).
In I'1RPL33A extracts there is a dramatic increase in the amount of extra-ribosomal SS
rRNA found near the top of the gradient (-41 % of the total SS RNA relative to -11 % for
wild-type extracts), while in other regions of the gradient the amount of 5S rRNA is
reduced. This latter observation is consistent with the absorbance tracings of the gradient
profiles which show an almost complete loss of free 60S subunits and a lower level of
polysomes including half-mer polysomes, relative to wild-type (Figure 7). As for the

MPL33A strain, extracts from the I'1SDOl strain show a significant reduction in the
amount of SS rRNA in the polysome region of the gradient compared to wild-type. In
contrast to extracts of the MPL33A strain, I'1SDOl extracts show a substantial peak of SS
rRNA in the 60S region with this peak being comparable to that of the wild-type strain.
The ratio of SS to S.8S rRNA in this peak is similar to that found in 80S and polysome
regions indicating that this free pool of 60S subunits contains stoichiometric amounts of
these two mature rRNA species.
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Figure 9. The yeast DBA model has an increased amount of extra-ribosomal 5S
rRNA. Each row depicts a total of 12 precipitated RNA fractions spanning the 7-47%
stepwise sucrose density gradients of resolved polysome extracts corresponding to wildtype (top rows), MPL33A (middle two rows), and f).SDOl (bottom two rows) yeast
strains. RNA samples were immobilized to nylon membranes via UV crosslinking and
incubated with radiolabeled oligonucleotide probes to either SS or S.8S rRNA (labels are
shown to the right). The percentage of extra-ribosomal SS rRNA for each yeast strain is
depicted to the left of each northern blot and is expressed as a mean. Student's t test was
used to test for statistical significance. The percentage of extra-ribosomal SS rRNA is
representative of the ratio of SS rRNA at the top of the gradient divided by the total SS
rRNA within a gradient. tWild-type versus mutant strains (p<O.004); :j: f).RPL33A versus

f).SDOl (p<O.OI).
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The increase in 5S rRNA in the 60S region in !1SDO 1 extracts is associated with a small
amount of extra-ribosomal 5S rRNA (-27% of total 5S RNA) found near the top of the
gradient when compared with the MPL33A strain. Thus, the two disease models differ
dramatically in their effect on subunit assembly and stability including differences in the
fate of 5S rRNA as a consequence of these distinct effects on 60S subunit maturation.

Discussion

The recent finding that DBA can be caused by mutations in genes encoding large
subunit ribosomal proteins has a number of implications (Farrar, Nater et al. 2008;
Gazda, Sheen et al. 2008). This observation now suggests that any of the approximately
60 genes encoding large subunit ribosomal proteins could be mutated in DBA patients
with unknown genetic lesions. Furthermore, this observation continues to support the
notion that DBA is caused by mutations in genes encoding structural components of the
ribosome and that either subunit can be affected. For the purposes of this study, the
finding that 60S subunit ribosomal proteins are affected in DBA allowed for a more
direct comparison of the underlying molecular bases for DBA and SDS, as the target in
SDS also appears to be the 60S ribosomal subunit (Ganapathi, Austin et al. 2007; Menne,
Goyenechea et al. 2007).
The yeast models of DBA and SDS examined here are both associated with a
selective reduction in the amount of 60S ribosomal subunits. This reduction is more
severe in the MPL33A extracts relative to !1SDOl extracts when total subunit analysis is
performed. In both cases, the reduced amount of 60S subunits is associated with the
appearance of half-mer polysomes upon polysome analysis. Half-mer polysomes are
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polysomes with stalled 48S initiation complexes generally linked to defects in 60S
subunit synthesis (Rotenberg, Moritz et al. 1988). In this case, subunit joining is delayed
in forming 80S initiation complexes leaving 48S initiation complexes stalled at the
initiation codon. The reduction in 60S subunits in the MPL33A strain occurs at the level
of 27S A2/A3 pre-rRNA processing, which results in delayed production of 27S B prerRNA and reduced amounts of mature 5.8S and 25S rRNA. A related defect in the
production of 60S ribosomal subunits has recently been demonstrated for a yeast strain
harboring a missense mutation in RPL33A (Martin-Marcos, Hinnebusch et al. 2007).
In the yeast model of SDS, half-mer polysomes are observed in cells that still
have a substantial pool of free 60S ribosomal subunits. These results differ dramatically
from those in a previous study of a !1SDOl deletion strain in which half-mer polysomes
were not observed despite an apparent reduction in the amount of 60S subunits (Menne,
Goyenechea et al. 2007). These previous findings are difficult to explain since studies
have shown that a reduction in 60S subunits gives rise to half-mer polysomes (Venema
and Tollervey 1999). My data reveal that there is also a delay in pre-rRNA processing in
the !1SDOl strain, but that this delay occurs at the level of 27S B pre-rRNA, downstream
of the effect observed in cells depleted of Rp133A. This delay is also associated with the
retention of a significant fraction of 60S subunits within the nuclei of !1SDO 1 cells.
Thus, the effect of the SDO 1 mutation on the amount of 60S subunits available for
translation in the cytoplasm represents a combined effect of both delayed pre-rRNA
processing and nuclear retention.

This interpretation is in general agreement with

conclusions reached previously on the role of Sdo 1 in recycling Tif6 from the cytoplasm
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to the nucleus where it is involved in 60S subunit maturation, but differs significantly
from the previous report in the supporting data (Menne, Goyenechea et al. 2007).
Comparing the two disease models, I have shown that they differ in their effect on
the maturation of 60S subunits (Figure 10). Both 35S pre-rRNA and 5S rRNA are found
in 90S pre-ribosomal particles assembled early in the ribosome maturation pathway
(Zhang, Harnpicharnchai et al. 2007). The maturation defect in the DBA model occurs
earlier in the pathway and is accompanied by the rapid degradation of incompletely
assembled precursors. In contrast, the maturation defect in the SDS model is associated
with delayed export, and accumulation of 60S-like particles in the nucleoplasm. Thus,
the differences in the mechanism by which ribosome maturation is disrupted in these
yeast models of DBA and SDS could form the basis for different types of
nucleolar/nuclear stress signaling and be responsible for the distinct clinical presentations
of the two diseases in humans.
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Figure 10.

Ribosomal subunit maturation in ARPL33A and ASDOI strains.

Diagrammatic representations of ribosomal subunit maturation in wild-type (top panel),
MPL33A (middle panel), and I1SDOl (bottom panel) yeast strains are shown and are

described in detail in the text. Orange circles represent either the 90S pre-ribosomal
particle or 40S or 60S ribosomal subunit precursors.

Fractured circles represent

precursor degradation. Relevant steps in pre-rRNA processing are labeled. 5S rRNA is
labeled and is shown in red.
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Accumulating data suggest that nucleolar stress signaling linked to abortive
ribosome assembly plays an important role in the pathophysiology of DBA. Studies in
zebra fish (Danilova, Sakamoto et al. 2008) and mouse (McGowan, Li et al. 2008)
models of DBA suggest that p53 stabilization and activation promoted by nucleolar stress
signaling is critical for phenotypes associated with ribosomal protein haploinsufficiency.
While many potential mechanisms can explain p53 activation and stabilization under
conditions of stress, recent studies have identified mechanisms more specific to nucleolar
stress induced by abortive ribosome assembly (Lindstrom, Deisenroth et al. 2007; Sun,
Dai et al. 2007). Three large subunit ribosomal proteins bind to MDM2 and promote p53
stabilization and activation. Two of these proteins, Rpl5 and Rp111, bind synergistically
with MDM2, most likely mediated through their interaction with 5S rRNA (Horn and
Vousden 2008). Therefore, I was interested in following the fate of 5S rRNA in the yeast
models of DBA and SDS to determine whether the maturation defects outlined above
influenced 5S rRNA assembly.
Intriguingly, both disease models show an increase in extra-ribosomal 5S rRNA
relative to wild-type. 5S rRNA is distinct from the other three mature rRNA species in
that 5S rRNA is transcribed by RNA polymerase III, distinct from the 35S polycistronic
precursor transcribed by RNA polymerase I, which gives rise to 25S, I8S, and 5.8S
rRNA (Venema and Tollervey 1999). Moreover, 5S rRNA forms a subcomplex with
Rp15, Rpl1I and specific assembly factors within 60S subunit precursors (Zhang,
Harnpicharnchai et al. 2007).

Whether this subcomplex forms prior to joining 60S

subunit precursors or after individual components of the subcomplex are incorporated
into maturing subunits has not yet been determined (Zhang, Harnpicharnchai et al. 2007).
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According to the data reported here, the extra-ribosomal pool of SS rRNA in wild-type
cells accounts for only about 10% of the total SS rRNA on sucrose gradients. This extraribosomal pool increases to approximately 40% of total SS rRNA in MPL33A extracts
(Figure 9). This increase could be a reflection of the inability of assembly intermediates
lacking Rp133A to stably incorporate components of the SS rRNA subcomplex into 60S
subunit precursors. The extent to which components of the SS subcomplex depend on
Rp133A for incorporation into assembling 60S subunits is currently unknown (Nissan,
Bassler et al. 2002).

The observation that depletion of Rp133A blocks pre-rRNA

processing upstream of 27S B pre-rRNA, which accumulates in cells depleted of
components of the SS subcomplex (Dechampesme, Koroleva et al. 1999; Zhang,
Harnpicharnchai et al. 2007), is consistent with Rp133A acting earlier in the pathway than
components of the SS subcomplex. It cannot, however, rule out the possibility that the
increased extra-ribosomal SS rRNA observed in cells depleted of Rp133A results from the
release of bound SS subcomplex from abortive assembly intermediates targeted for
degradation.
In contrast to the data obtained with the MPL33A strain, my data show that SS

rRNA co-sediments with the large pool of free 60S subunits observed in I'1SDOl cells.
The localization data indicate that a considerable fraction of this pool of free 60S subunits
in I'1SDOl cells is retained within the nucleus. This pool of free 60S subunits likely
represents pre-60S subunit precursors containing either 27S B pre-rRNA or pre-60S
subunit precursors even further along the maturation pathway containing mature 2SS and
S.8S rRNA (Harnpicharnchai, Jakovljevic et al. 2001). The ratio of SS to S.8S rRNA in
the free 60S subunit peak is similar to the ratio of SS to S.8S rRNA in functional 60S
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subunits found in the polysome fractions, indicating that 5S rRNA has been incorporated
into the nuclear-retained subunits in !1SDOl cells. The decreased amount of total 60S
subunits in these cells suggests that this pool of pre-60S subunits may be turned over at a
higher rate than mature 60S subunits that reach the cytoplasm.

It is an interesting

possibility that the increased amounts of extra-ribosomal 5S rRNA in !1SDO 1 strains may
be a consequence of the release of the 5S subcomplex from pre-60S particles targeted for
degradation.
Some caveats should be considered in regarding an integral role for components
of the 5S rRNA subcomplex in signaling mechanisms that link abortive ribosome
assembly to p53 stabilization and activation as a molecular basis for DBA. First, it is the
general view that the assembly of 60S ribosomal subunits is largely independent of the
assembly of 40S subunits, suggesting that haploinsufficiency for a small subunit
ribosomal protein should not interfere with steps in 60S subunit assembly. However,
recent results from mammalian systems reveal that disruption of 40S subunit maturation
results in an up-regulation of translation of Rp111 (Fumagalli, Di Cara et al. 2009). This
up-regulation presumably results in Rpl11 being synthesized in excess of that needed for
60S subunit assembly which in turn, interacts with MDM2 leading to p53 activation.
These studies did not however, address whether Rplll functions in concert with other
components of the 5S rRNA subcomplex in this signaling pathway. A second caveat
with regard to a critical role for Rpl5 and Rp111 signaling in the pathophysiology of DBA
is the finding that RPL5 and RPLll are both mutated in DBA (Gazda, Sheen et al. 2008).
Here it is difficult to envision how proteins that presumably limit ribosome assembly in
an affected patient could also have an important role in signaling via an interaction with
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MDM2. The observation that patients with mutations in RPL5 have distinct clinical
phenotypes suggests that alternative signaling pathways may operate in patients with
mutations in RPL5 and RPLII (Gazda, Sheen et al. 2008).
Despite the caveats, these yeast data support a potential role for the 5S
ribonucleoprotein subcomplex in the pathogenesis of DBA. Moreover, the differences in
the mechanisms by which 60S subunit maturation is affected in the DBA and SDS
models and their influence on the 5S subcomplex suggest that this subcomplex may also
be important in explaining how defects in the maturation of 60S ribosomal subunits can
give rise to distinct clinical phenotypes.
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CHAPTER III
THE SBDS FAMILY OF PROTEINS REGULATE 60S SUBUNIT MATURATION BY
MODULATING PROTEIN ACETYLATION

Introduction
Shwachman-Diamond syndrome (SDS) is a member of a group of rare congenital
bone marrow failure syndromes whose molecular basis has been connected to faulty
ribosome biosynthesis or function. Patients with this disorder manifest a wide collection
of clinical features, which notably include hematological abnormalities, pancreatic
dysfunction, growth retardation, and enhanced cancer susceptibility.

The typical

hematological profile of an SDS patient involves intermittent or persistent neutropenia,
though other cell lineages may be affected. A paucity of neutrophils in the peripheral
blood together with exocrine pancreatic insufficiency and metaphyseal chondrodysplasia
are considered hallmark diagnostic features of SDS.

Patients may also present with

developmental delays and other congenital abnormalities.
In 2003, mutations of the SBDS locus were found to be present in most patients
with SDS (-89%) (Boocock, Morrison et al. 2003). Studies on SDO 1, the yeast ortholog
of SBDS, support a role for the SBDS family of proteins in 60S subunit maturation. Sdo 1
appears to perform this function by controlling the dissociation of the anti-association
factor Tif6 from nascent 60S subunits in the cytoplasm. Without Sdo 1, Tif6 remains
associated with 60S subunits in the cytoplasm thereby preventing its recycling to the
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nucleolus where it participates in late steps in subunit maturation (Menne, Goyenechea et
al. 2007). Human studies have demonstrated physical interactions between SBDS and
60S subunits (Ganapathi, Austin et al. 2007) and further studies investigating an SDS
murine model revealed that Sbds is necessary for 60S subunit biogenesis (Ball, Zhang et
al. 2009). Together, these observations suggest a potential role for the SBDS family of
proteins in large subunit maturation and/or function. My studies in yeast demonstrate
that Sdol is required for the late stages of 60S subunit maturation (Moore IV, Farrar et al.
2009).

I also show yeast strains depleted of Sdo 1 possess half-mer polysomes as a

consequence of a reduction in the number of functional 60S ribosomal subunits in the
cytoplasm. In addition to its suggested role in subunit maturation, SBDS plays a role in
chemotaxis (Stepanovic, Wessels et al. 2004; Wessels, Srikantha et al. 2006; Orelio and
Kuijpers 2009), and also functions in mitotic spindle stabilization and the maintenance of
genomic stability (Austin, Gupta et al. 2008). Thus, the SBDS family of proteins appears
to possess multiple cellular functions.

The molecular mechanisms by which they

coordinate and/or function in these cellular processes are currently unknown.
In collaborative efforts with the laboratory of Paul de Figueiredo at Texas A&M
University, we demonstrate a novel role for the SBDS family of proteins in the
maintenance of protein acetylation by acting as endogenous inhibitors of cellular histone
deacetylase (HDAC) activities. The de Figueiredo laboratory demonstrated that Sdo 1
physically and genetically interacts with yeast class I (Rpd3) and class II (Hdal) histone
deacetylases to antagonize their activity (submitted to Cell). In a collaboration with the
de Figueiredo laboratory, we demonstrated that pharmacological and genetic inactivation
of class I and class II HDAC enzymes ameliorates the ribosome biogenesis defect
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associated with the depletion of Sdo 1 in a yeast model of SDS. This amelioration is
manifested by a restoration of growth, an increase in mean polysome size, and a partial
resolution of half-mer polysomes. These observations suggest that Sdo 1 might regulate
60S subunit maturation by modulating one or more protein acetylation events.
Fluorescence localization studies revealed the relocalization of nucleolar retained GFP
tagged 60S ribosomal subunits to the cytoplasm upon inhibition of HDAC activity in
yeast strains depleted of Sdol (Paul de Figueiredo; unpublished results). In light of these
observations, I hypothesized that the inhibition of HDAC activity by Sdol was necessary
for the efficient export of 60S subunits to the cytoplasm through its ability to modulate
the association of Tif6 with 60S ribosomal subunits. In support of this model, I show
ribosome-enriched extracts contain a higher content of Tif6 in SDOI mutants relative to
wild-type strains. Moreover, the enhanced association of Tif6 with 60S subunits can
become partially reversed by the pharmacological or genetic inactivation of histone
deacetylase activities. Overall, these studies establish a novel relationship between the
function of the SBDS family of proteins, protein acetylation, and ribosome maturation.
This work also has implications for SDS pathophysiology and predicts a new potential
class of therapeutic agents for treating patients with SDS.
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Design and Methods
Yeast strains
Most of the haploid strains employed in these studies are derivatives of BY4743
(MAT ala his311lhis311, leu211lleu211, lys2DI+, metJ5111+, ura311lura311) or W303 (MAT

ala his3lhis3, leu2lleu2, ura3lura2, trpJltrpJ, ade2lade2, canJ/canJ) yeast genetic
backgrounds supplied by Dr.'s Jinbai Guo and James Huang. The strains and relevant
genotypes utilized in these studies are shown in table 1.

Trichostatin A drug treatments
A 3mM stock solution of TSA was prepared by reconstitution of lyophilized TSA
powder (lnvivoGen, Inc., San Diego, CA, USA) in dimethylsulfoxide. The stock solution
was diluted (in growth media) to concentrations employed in individual experiments.

Polysome analysis and protein precipitation
Yeast strains were grown to mid-log phase in YPG, YPD, or YPD containing 0.5,
1.0, 2.0, or 5.0flM TSA. Cell extracts were prepared for polysome analysis as outlined
previously (Leger-Silvestre, Caffrey et al. 2005). Extracts were centrifuged at 28,000
RPM for 6 hours in an SW28.1 rotor (Beckman Instruments, Inc., Fullerton, CA, USA).
Following centrifugation, stepwise sucrose gradients (7-47%) were fractionated and the
absorbance at 254nm monitored using an ISCO model 185 gradient fractionator
interfaced to a UA-6 absorbance detector (Teledyne Isco, Inc., Lincoln, NE, USA).
Resultant polysome profiles were subjected to peak integration (corresponding to 60S,
80S, and polysome regions) to determine relative percent areas under the curve.
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Table 1
Yeast Strains Utilized

0'\

00

BY4741
JHY980
SRYR35
JGY040
MPD3, MiDA1 , !1SDOl
W303 !1SDOl
BY!1SDOl

MAT a his3L1. leu2L1. met15L1. ura3L1
MAT? H1S3MX6::GAL1-SD01, his3L1, leu2L1, ura3L1
MAT a hdal::TRP1, rpd3::LEU2, ade2, his3
MAT a kanMX6::GAL-SD01. hdal::TRP 1
MAT? sdol::kanMX4ISD01, his3, ura3, ade2, leu2,
MAT? sdol::kanMX4ISD01, his3L1, leu2L1, ura3L1

ade2

Protein was recovered from sucrose gradient fractions after precipitation with
1: 100 volumes of 2% sodium deoxycholate (DOC) and 1:5 volumes of trichloroacetic
acid (TCA). Eppendorf tubes containing precipitated protein fractions were placed on ice
for 1 hour and centrifuged at 13,000 RPM (-16,000 x g) in a tabletop centrifuge at 4°C
for 15 minutes. The resultant supernatant was carefully discarded (aspirated off) and 600
!!L of -20°C acetone added to wash pelleted proteins. This washing step was repeated
prior to allowing pelleted proteins to air-dry in an inverted position on paper towels.
Protein precipitates were resuspended in NuPAGE@ LDS sample dilution buffer (under
reducing conditions) and resolved on NuPAGE@ 4-12% Bis-Tris Gels (InvitrogenTM,
Carlsbad, CA, USA).

Preparation of yeast whole cell extracts

Yeast strains were grown in 100 mL of glucose rich media (YPD) to mid-log
phase. Cells were centrifuged for 10 minutes at 5,000 RPM (-3,000 x g) and washed two
times with cell lysis buffer (20 mM Tris-HCI [pH 7.6], 10 mM NaF, 10 mM sodium
pyrophosphate, 0.5 mM EDTA, 0.1 % deoxycholate). Cell pellets were resuspended in
100 IJLs of cell lysis buffer and 0.30 grams of 425-600 micron glass beads were added.
Cell suspensions were then vortexed at high speed, 8 times, 30 seconds each, with 30
second cool down periods between bursts. Following this cell lysis procedure, extracts
were centrifuged at 5,000 x g at 4°C for 1 minute to remove unbroken cells. Lastly,
using a gel-loading pipette tip, extracts are withdrawn from the top of glass bead slurries,
placed in eppendorf tubes, and stored in -80°C for later use.
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Differential centrifugation and ribosome enrichment
Ribosome enriched fractions were derived from polysome extracts isolated via a
variation of a method outlined previously for polysome analysis (Leger-Silvestre, Caffrey
et al. 2005). Yeast strains were inoculated into 100 ml of glucose rich media (YPD) and
were allowed to grow to mid-log phase at 30°C. Cycloheximide (5 mg) was added to
flasks containing cells and media, swirled, and poured into chilled nalgene® centrifuge
bottles.

Cells were collected by centrifugation at 5,000 RPM (-3,000 x g) for 10

minutes, supernatants decanted, and resultant pellets resuspended in 5 ml of polysome
buffer (10 mM Tris-HCI [pH 7.5], 100 mM NaCI, 30 mM MgCh, 50 IJg/ml
cycloheximide, 100 IJg/ml heparin, 0.2 IJl/ml DEPC). Cell suspensions were transferred
to 12 ml pop-top tubes, centrifuged again, and the washing step repeated with polysome
buffer. Cell pellets were resuspended in 400 IJI of polysome buffer and 0.30 grams of
425-600 micron glass beads were added. Cell suspensions were then mechanically lysed
by vortexing at high speed, 8 times, 30 seconds each, with 30 second cool down periods
between bursts. Following cell lysis, extracts were centrifuged at 5,000 x g at 4°C for 1
minute to remove unbroken cells and debris. Next, approximately 400 IJI of cell extracts
were withdrawn from glass bead slurries using gel-loading pipette tips, and placed in 11 x
34 mm Beckman thickwall polycarbonate tubes (Beckman Coulter, Inc., Brea, CA,
USA). Differential centrifugation was carried out using a TLA-100.2 fixed-angle rotor
(Beckman Coulter, Inc., Brea, CA, USA). First, samples were centrifuged at 17,000
RPM (10,000 x g) for 10 minutes to pellet cell walls, nuclei, and organelles. Resultant
supernatants were then transferred to new Beckman polycarbonate tubes and centrifuged
at 75,000 RPM (200,000 x g) for 30 minutes to isolate ribosome pellets. Following the
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final high speed (75,000 RPM) centrifugation step, ribosome pellets were suspended
(using polysome buffer) in volumes required to attain final concentrations of 5 mg/ml.

Western blot analysis
Protein extracts were resolved on NuPAGE® 4-12% Bis-Tris Gels (InvitrogenTM,
Carlsbad,

CA,

USA),

using

standard

IX

MES

SDS

electrophoretically transferred to nitrocellulose membranes.

running

buffer,

and

Membranes were then

blocked for 1 hour in blocking buffer (lX TBS, 0.1 % Tween-20 with 5% w/v nonfat dry
milk), rinsed with TBS-T

OX TBS, 0.1 % Tween-20), and incubated overnight at 4°C

with primary antibodies in primary antibody dilution buffer (lX TBS, 0.1 % Tween-20
with 5% BSA).

Primary antibodies employed include: rabbit polyclonal against

acetylated-Iysine (Cell Signaling Technology, Inc., Danvers, MA, USA), mouse
monoclonal against beta Actin [mAbcam 8224] (Abcam, Inc., Cambridge, MA, USA),
rabbit polyclonal against human EIF6 (Proteintech Group, Inc., Chicago, IL, USA), and
mouse polyclonal against RPLPO (Abnova Corporation, Taipei, Taiwan). The RPLPO
antibody cross-reacts with yeast Rp14, which was used as a control.

Following

incubation with primary antibodies, membranes were washed three times, for 10 minutes
each, with TBS-T and then incubated with the appropriate HRP-conjugated secondary
antibodies in blocking buffer for 1 hour at room temperature.

Secondary antibodies

employed include: HRP-linked goat to rabbit IgG [#7074] (Cell Signaling Technology,
Inc., Danvers, MA, USA) and HRP-linked rabbit to mouse IgG [mAbcam 6728] (Abcam,
Inc., Cambridge, MA, USA). Again, following this incubation period, membranes were
washed three times for 5 minutes each with TBS-T wash buffer. Proteins were detected
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using the ECL Plus Western Blotting Detection System from GE Healthcare (GE
Healthcare Biosciences, Piscataway, NJ, USA), as suggested by the manufacturers
instructions.

Results
We have recently entered into collaboration with the laboratory of Dr. Paul de
Figueiredo (Texas A&M University) who had performed a high throughput screen of
more than 160,000 unique small molecules in an effort to identify potential compounds
that ameliorate or suppress the growth defect associated with the depletion of Sdo 1. The
overall goal of this screen was to gain a better understanding of the molecular function of
Sdol and to identify potential lead compounds for therapeutic development. A diversity
of structural classes of compounds was identified in this screen including a number of
histone deacetylase inhibitors. I chose one of these inhibitors, trichostatin A (TSA), for
further study.

The structure of TSA is shown in Figure 11, panel A.

TSA is a

commercially available antifungal antibiotic, which acts as a specific and potent inhibitor
of class I and class II histone deacetylases (HDACs). HDACs function as parts of large
multi-subunit complexes that have essential roles in various cellular processes (Yang and
Seto 2003; Yang and Seto 2008). HDACs are categorized into four groups according to
sequence homology, as well as function, and include the "classical" family, which is
grouped into classes I, II, and, IV (Yang and Seto 2008), and the the sirtuin family of
NAD+-dependent deacetylases which constitute class III.

Most class I HDACs are

subunits of multimeric nuclear complexes that modulate chromatin structure and
transcriptional activity, whereas class II HDACs regulate processes in the cytoplasm or
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function to transmit signals between the cytoplasm and nucleus by shuttling between the
two compartments (Yang and Seto 2008). Little is known about the class IV group, and
based on its sequence similarities to other HDACs, is considered a unique class of its own
(Yang and Seto 2008).
To test the efficacy of TSA in suppressing the slow growth phenotype associated
with the loss of SdoI, an inducible SDOl deletion strain (4D) was treated with increasing
concentrations of this pharmacological HDAC inhibitor (Figure 11, Panel B). SDOl
expreSSIOn in this strain was under the control of a galactose-inducible/glucoserepressible GAL1-10 promoter (pGAL-SDO 1).

In addition, this strain also contained

deletions in three multi-drug resistance genes (PDR5, SNQ2, and ERG6) to aid in drug
delivery and cellular retention. In panel B of Figure 11, cellular growth was severely
impaired under conditions where SDO 1 expression was repressed (in the presence of
glucose). TSA treatment resulted in a dose-dependent increase in growth rate of the
Sdo I-depleted yeast strain with increasing concentrations of TSA up to 5

~M.

TSA

treated Sdo I-depleted yeast strains also exhibited a dose-dependent increase in polysome
size and partial resolution of half-mer polysomes, as evidenced by polysome analysis in
panel C of Figure 11.
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Figure 11. TSA partially rescues the slow growth phenotype associated with the

depletion of Sdol. (A) The structure of the pharmacological class I and class II HDAC
inhibitor, trichostatin A. (B) 4D and wild-type (WT) yeast strains were pre-grown for 24
hours in glucose rich liquid media. Following this incubation period, five serial dilutions
were prepared and spotted on solid YPD media, from top to bottom, with increasing
dilution. From left to right the media contained increasing concentrations of TSA (0, 0.5,
1, 2, or 5 ~M).
(bottom).

Cells were grown at 30° C and imaged at 72 hrs (top) and 96 hrs

(C) Polysome analysis of strain 4D grown in galactose (Sdol expressed),

glucose (Sdol depleted), or glucose rich media containing 0.5, 1.0,2.0, or 5.0
74

~M

TSA.

A semi-quantitative analysis of 5 IJM TSA treated and untreated Sdo I-deficient
polysome profiles was performed by determining the relative percent area of 60S, 80S,
and polysome regions in absorbance tracings (Figure 12). The relative percent of areas
for these specific regions (i.e. 60S, 80S, and polysome regions) are represented as the
peak area divided by the total area (ineludes all three regions). Relative to untreated
strains, the Sdol-depleted yeast strains treated with 5 IJM TSA revealed a net decrease in
the percentage of free 60S subunits and 80S monomers, with a corresponding overall
increase in polysomes (Figure 12, Panel B). My previous work has demonstrated that the
loss of Sdo 1 interferes with the nueleo-cytoplasmic transport of 60S ribosomal subunits,
which results in nuclear retention of pre-60S particles, a severe reduction in the quantity
of functional polysomes, and the appearance of half-mer polysomes (polysome peaks
possessing shoulders) containing stalled 48S initiation complexes (Moore IV, Farrar et al.
2009). Because of this block in nuclear export, the polysomes profiles of Sdo 1 mutant
strains possess a large free 60S peak, composed primarily of 60S pre-ribosomes retained
in the nueleus. In Figure 12, the size of this peak is reduced in TSA treated cells with a
corresponding increase in total polysomes. These data suggest that TSA partially rescues
the ribosome maturation defect associated with the loss of Sdo 1 and enhances the
availability of 60S subunits to participate in translation.

Based on this evidence, I

hypothesize that TSA treatment enhances 60S subunit transport from the nucleus to the
cytoplasm and consequently makes more large ribosomal subunits accessible for
translation in the Sdo 1 depleted strain. Questions remained as to the mechanisms by
which this HDAC inhibitor resolves the ribosome defect associated with the depletion of
Sdol.
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Trichostatin A treatment partially corrects the ribosome maturation

defect associated with the loss of Sdol. (A) Representative polysome profiles from
strain 4D harvested from glucose containing media (SD01 expression repressed) or
glucose containing media with 5.0 IJM TSA. The number of trials used for quantitative
analysis is denoted with the letter n. (B) Quantification of 4D polysome absorbance
tracings. Relative percent area (% area) of 60S, 80S monomers, or polysome regions
were determined and averages shown. Columns representative of TSA treated samples
are labeled with plus signs (+), and those untreated are labeled with minus signs (-).
Error bars corresponding to the standard error of the mean (SEM) are shown. Statistical
significance was assessed by Student's t test and P-values are displayed.
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Since TSA is a known histone deacetylase inliibitor, it seemed reasonable to
determine if genetically eliminating the enzyme target of TSA could also partially
compensate for the absence of Sdo 1. Yeast possess 13 annotated HDAC genes which
include: RPD3, HDA1, HDA2, HDA3, HOS1, HOS2, HOS3, HOS4, HST1, HST2, HST3,
HST4, and SIR2. Of these genes, RPD3 and HDAl (HDAl activity requires HDA2 and
HDA3), the major yeast class I and class II HDACs, respectively, are inhibited by TSA
(Bernstein, Tong et al. 2000). The class III NAD+-dependent (HSTl, HST2, HST3, HST4,
and SIR2) deacetylases and HOS3 (HOS3 shows similarity to RPD3 and HDA1)
deacetylases are insensitive to TSA; little is known regarding HOS1, HOS2, and HOS4
(Bernstein, Tong et al. 2000; Yang and Seto 2008). Using a serial dilution-plating assay,
the Paul de Figueiredo laboratory at Texas A&M monitored the growth of Sdo I-deficient
yeast strains that also harbored deletions in each of the 13 annotated yeast HDAC genes
(unpublished results). Most strains did not show measurable improvement in growth,
however, strains harboring deletions in either RPD3 or HDAl showed a marked increase
in growth. These data suggested that SDOl cooperates in a genetic pathway involving
the class I and/or class II family of HDAC genes. A strain was therefore created that
contained the pGal-SDOl construct as the only source of Sdol together with null alleles
of RPD3 and HDA1. The ability of the loss of these histone deacetylases to compensate
for the reduced amounts of Sdol was assessed by growth on glucose (Figure 13, Panel
C).
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Figure 13. Loss of major class I and class II HDAC enzymes rescues the ribosome

maturation defect associated with the loss of Sdol. Polysome analysis of yeast strains:
(A) Strain JHY980, conditional pGal-SDOl strain grown in galactose (top) or glucose
(bottom). (B) Strain SRYR35, control strain containing wild-type SDOl and two null
alleles for RPD3 and HDA1, grown in galactose (top) or glucose (bottom). (C) Strain
JGY040, conditional pGal-SDOl strain containing RPD3 and HDAl null alleles, grown
in galactose (top) or glucose (bottom). (D) Sdol-deletion strain (W303 L1SD01) grown
in glucose (top) and RPD3, HDA1, SDOl triple-deletion strain grown in glucose
(bottom).
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As previously demonstrated, under conditions where SDOl expression is repressed
(Figure 13, Panel A, glucose), absorbance tracings show evidence of translational stress
underscored by a dramatic decrease in polysomes and the appearance of half-mer
polysomes relative to strains grown in galactose (Figure 13, Panel A, galactose). As
predicted, the effects of Sdol depletion were largely rescued by the absence of RPD3 and
HDA1.

Panel C of figure 13 (glucose) shows that polysome profiles from the strain

lacking Rpd3 and Hdal have a marked increase in translation with only a modest
presence of half-mer polysomes that were virtually indistinguishable from the strain
grown in galactose (Figure 13, Panel C, galactose). In a control strain, containing wildtype SD01, deletion of RPD3 and HDAl (both of which are not essential) in the presence
of galactose or glucose did not produce any observable affects on the translational
machinery of cells (Figure 13, Panel B).
The transcriptional activity of a gene is largely influenced by chromatin structure
(Wolffe 1998). Further, covalent modification of histones via the acetylation of lysine
residues can alter chromatin structure to activate gene transcription. Thus, suppression of
the Sdo I-depleted phenotype in the conditional pGal-SDO 1 strain (grown in glucose)
mediated by the deletion of two major cellular HDACs, RPD3 and HDA1, may actually
be the result of de-repression of the galactose-inducible promoter used to deplete cells of
Sdo 1. To address this concern, polysome analysis was performed on a triple-deletion
strain where an SDOl null allele was combined with deletions in RPD3 and HDAl
(Figure 13, Panel D). Thus, we were asking whether the loss of Rpd3 and Hdal could
compensate for the complete loss of Sdol. The polysome profile of the triple deletion
strain, like that obtained with the conditional pGal-SDOl strain (Figure 13, Panel C,
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glucose), revealed a mean increase in polysome size and a resolution of half-mer
polysomes when compared with an Sdol deletion strain alone.
Taken as a whole, these experiments demonstrate the loss of major elass I and
elass II HDAC enzymes, either by pharmacological inhibition (TSA-mediated) or by
genetic inactivation, rescues the ribosome biogenesis defect associated with the loss of
Sdo 1. These observations suggest that Sdo 1 may participate in 60S subunit maturation
by modulating protein acetylation through its function as an endogenous histone
deacetylase inhibitor. I hypothesize that in the absence of Sdo 1, unregulated deacetylase
activity disrupts normal nueleo-cytoplasmic 60S ribosomal subunit transport. Moreover,
these data indicate that inhibition of histone deacetylase activity with a small molecule
pharmacological agent can partially compensate for the loss of Sdol and overcome this
defect.
I suspect that one or more proteins positioned in this export pathway require
acetylation for efficient 60S subunit export from the nueleus to the cytoplasm. Whole
cell immunoblots using antisera raised to acetylated-Iysine revealed differences in
acetylation between wild-type and SDOi-null cells (Figure 14, Panel A). Consistent with
Sdol 's proposed role as an HDAC inhibitor, both the conditional Sdol-depleted strains
(4D) and the SDOi-deletion strains (BYllSdoI) show a relative reduction in lysine
acetylation of numerous low molecular weight proteins (-15-50 kDa range) compared to
wild-type strains. Notably, this hypo-acetylated phenotype is more pronounced in the
SDO i-deletion strains than that of the Sdo I-depleted strains (Figure 14, Panel A).
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Figure 14.

The loss of Sdol is associated with alterations in protein acetylation.

Western blot analysis of (A) whole cell extracts derived from BY4741, BY!1SD01, 4D,
or 4D yeast strains treated with 5 IJM TSA and (B) cellular fractions (whole cell,
ribosome, and supernatant) obtained by differential centrifugation of BY4741 or 4D yeast
strains. Whole cell extracts were centrifuged at 17,000 RPM (low-speed) and then at
75,000 RPM (high-speed) to pellet soluble/cytosolic ribosomes.

Whole cell extracts,

ribosome enriched fractions, and resultant high-speed supernatants were diluted in equal
volumes of buffer and equivalent volumes resolved on 4-12% SDS-PAGE gels.
Antibodies used include acetylated-Iysine antibody (Ac-Lys; 1: 1000 dilution), beta-actin
antibody (Actin; 1: 1000 dilution), Tif6 antibody (1: 1500 dilution), and RPLPO antibody
(1:500 dilution).

The RPLPO antibody is a mouse polyclonal IgG raised against the

human ribosomal protein RPLPO and has confirmed cross-reactivity with the yeast large
ribosomal subunit protein L4 (RPL4).
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In addition, the conditional Sdo I-depleted strains (4D) prepared in glucose containing 5
tJM TSA showed evidence that this HDAC inhibitor was capable of rescuing protein
acetylation whereas several low molecular weight proteins (-15-50 kDa range) in treated
strains possessed modest increases in lysine acetylation relative to untreated strains.
Despite the apparent differences among wild-type and SD01-null cells, the large number
of proteins acetylated in whole cell extracts interfered with the ability to identify specific
protein targets of Sdolp-regulated acetylationJdeacetylation.
To minimize the number of acetylated proteins detected and, more importantly,
home in on translational machinery components whose acetylation is modulated by the
presence or absence of Sdo 1, I decided to enrich for ribosomal proteins and associated
factors by isolating crude ribosome fractions via differential centrifugation of whole cell
extracts (Figure 14, Panel B).
acetylated lysine antibodies.

These fractions were then immunoblotted with antiIn Figure 14, the ribosome-enriched fractions revealed

evidence of differential acetylation among wild-type and Sdo I-depleted yeast strains.
Unexpectedly, the ribosome-enriched fractions also revealed that a large number of
ribosomal proteins are apparently subject to 8-amino-Iysine side chain acetylation. This
particular posttranslational modification (PTM) had not been reported for ribosomal
proteins. Interestingly, while I was were bewildered by the relatively large number of
ribosomal proteins that possess acetylation of their lysine residues, Choudhary and
colleagues recently reported that a substantial number of mammalian ribosomal proteins
are subject to lysine acetylation (Choudhary, Kumar et al. 2009).
significance of these modifications remains largely unknown.

The biological

As with whole cell

acetylated-Iysine immunoblots, insufficient resolution of acetylated proteins limited the
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ability to identify individual proteins differentially acetylated between wild-type and

SD01-null derived ribosome extracts (Figure 14, Panel B).
Further fractionation of acetylated proteins was performed by immunoblotting
precipitated proteins isolated from polysome extracts, which were resolved on 7-47%
sucrose gradients.

In Figure 15, the acetylated-Iysine immunoblots of fractionated

polysomes revealed that proteins of both 40S and 60S ribosomal subunits were
acetylated.

Moreover, acetylation was observed in both free subunits and subunits

actively engaged in translation. The relative amount of acetylation in fractions across the
gradients of fractionated polysome profiles from wild-type, conditional Sdol-depleted,
and TSA treated Sdo I-depleted yeast strains showed a rough correspondence with the
total protein in each fraction.

This can be observed by comparing acetylated-Iysine

immunoblots with Coomassie stained gels below each blot in Figure 15 (bottom two
panels).

Because of the number of ribosomal proteins acetylated and the limited

resolution of I-dimensional gels, I was not able to identify specific ribosomal proteins or
ribosome associated factors whose acetylation was specifically modulated by the
presence or absence of Sdo 1.
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Figure 15. Sucrose density fractionation reveals proteins of both the 40S and 60S

ribosomal subunits are subject to lysine acetylation. Yeast cell extracts from strains
grown in glucose-containing media were subjected to polysome analysis (top panel). (A)
BY4741 (Wild-type SD01) strain, (B) 4D (I1Sdol::Gall-10 SD01) strain, or (C) 4D
(I1Sdol::Gall-10 SD01) strain grown in the presence of 5 flM TSA. Proteins were
precipitated and recovered from each of the corresponding fractions (12 in total) and
resolved on 4-12% SDS-PAGE gels.

Resultant gels were immunoblotted with anti-

aceylated lysine antibody (Ac-Lys; 1: 1000 dilution) (middle panel) or stained with
Colloidal Coomassie Blue stain (bottom panel).
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As I have previously demonstrated, cells lacking Sdo 1 accumulate half-mer
polysomes as a consequence of the failure to efficiently transport pre-60S subunits from
the nucleus to the cytoplasm (Moore IV, Farrar et al. 2009). This transport defect is
rescued by pharmacological or genetic inhibition of major class I and class II histone
deacetylases.

My efforts towards the identification of key proteins whose degree of

acetylation is reduced in Sdo 1 mutants and restored by TSA, have been hampered by the
limited resolution of I-dimensional gels.

I therefore asked a more specific question

pertaining to the role of acetylation in 60S subunit transport from the nucleus to the
cytoplasm. Previous studies implicated the protein Tif6 in the mechanism of action of
Sdol (Menne, Goyenechea et al. 2007). These studies suggested that Sdol is necessary
for the release of Tif6 from 60S ribosomal subunits in the cytoplasm so it can be recycled
to the nucleolus to participate in further rounds of 60S subunit export. In the absence of
Sdo 1, nuclear Tif6 becomes depleted and subsequently accumulates in the cytoplasm,
presumably due to it's inability to be recycled from nascent 60S subunits (Menne,
Goyenechea et al. 2007) (reviewed in Figure 16).
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Tif6

Wild-type

~.

Sdo1

LiSD01

Figure 16.

Sdol and Tif6 cooperate in a pathway required for the maturation,

nuclear export, and translational activation of 60S ribosomal subunits. Wild-type
(top panel) and !J.SDOl (bottom panel) are shown.

Black circles represent various

ribosomal particles. Tif6 (translation initiation factor 6) and Sdo1 (Shwachman-Diamond
ortholog protein) are labeled and are represented by red octagons or green cubes,
respectively. Messenger RNA (mRNA) is depicted by the yellow lines.
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In Figure 14, I show an inverse relationship between ribosomal protein acetylation
and the presence of Tif6 in ribosome fractions. Thus, there is a greater amount of Tif6
co-sedimenting with ribosomal subunits in the Sdo I-depleted yeast strain relative to wildtype cells. These observations also held true in yeast strains derived from both BY and
W303 genetic backgrounds (Figure 17, panel B) and are consistent with a role for Sdo I in
modulating the release of Tif6 from 60S ribosomal subunits by acting as an inhibitor of
histone deacetylase activity.

I further investigated the role of lysine acetylation in

mediating the interaction of Tif6 with 60S ribosomal subunits by addressing whether the
increase in the amount of Tif6 associated with ribosome fractions from Sdo I-deficient
strains could be reversed by the chemical or genetic inhibition of HDAC activity (Figure
17). To determine if the association of Tif6 with ribosome extracts is influenced by
histone deacetylase activity, the amount of Tif6 co-sedimenting with ribosomal subunits
in Sd01-depleted yeast strains was assessed in both the presence and absence of 5.0 J.lM
TSA. Sdo I-depleted strains grown in the presence of TSA showed a reduction in the
amount of Tif6 co-sedimenting with the ribosome fractions relative to untreated yeast
strains depleted of Sdo 1 (Figure 17, panel C).

To confirm that this result was a

consequence of the inhibition of class I and class II HDAC enzyme activities, the amount
of Tif6 present in ribosome fractions was assessed in strains harboring null alleles of
RPD3 and HDAI.
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Figure 17. The inhibition of yeast class I and class II HDA Cs reverse the enhanced

association of Tif6 with ribosomal fractions in SDOl-depleted yeast strains. (A)
Schematic hypotheses for the role of lysine acetylation in modulating the interactions of
Tif6 with 60S subunits. Left, in the absence of Sdo 1, unregulated HDAC activities of
Rpd3 and Hdal result in the loss of protein acetylation and the enhanced association of
Tif6 with 60S ribosomal subunits.

Right, the inhibition of Rpd3/Hdal HDACs via

genetic inactivation or TSA exposure, results in protein hyperacetylation, which in turn
favors the dissociation of Tif6 from 60S ribosomal subunits. (B) Immunoblot analyses of
crude ribosome fractions derived from

~Sdo 1 or

isogenic wild-type yeast strains in either

BY4743 (top) or W303 (bottom) genetic backgrounds and (C) 4D conditional Sdoldepleted

(~Sdol),

4D conditional Sdol-depleted grown in 5

TSA), or triple-deletion

(~Sdol ~Rpd3 ~Hdal)

~M

TSA

(~Sdol

+

5~M

yeast strains. Cells were mechanically

lysed with glass beads and ribosome fractions isolated using previously described
differential centrifugation techniques. For each sample, lOJlg of protein was loaded and
resolved on 4-12% SDS-PAGE gels. Immunoblot analyses was performed using antiTif6 antibodies (1:1500 dilution) or antibodies raised to RPLPO (1:500 dilution). As was
previously noted, the RPLPO antibody cross-reacts with the yeast large ribosomal subunit
protein L4 (RPL4).

89

Panel C of Figure 17, shows a dramatic decrease in the amount of Tif6 in ribosome
fractions of cells lacking Rpd3 and Hdal. The release of Tif6 from ribosome fractions
was greater in strains missing Rpd3 and Hdal relative to strains treated with TSA. The
amount of Tif6 present in the ribosome fractions correlated with the degree of
suppression of the Sdo I-mutant phenotypes by similar treatments (Figures 13 and 14).
These data suggest the HDAC-inhibitory activity of Sdo 1 is important for mediating
interactions between Tif6 and 60S ribosomal subunits and that in the absence of Sdol,
pharmacological inhibition of HDAC activities can ameliorate the subunit export defect
associated with its loss by aiding in the dissociation of Tif6 from 60S ribosomal subunits.

Discussion

Numerous studies show that the SBDS family of proteins function in the
maturation of 60S ribosomal subunits (Ganapathi, Austin et al. 2007; Menne,
Goyenechea et al. 2007; Ball, Zhang et al. 2009; Luz, Georg et al. 2009; Moore N,
Farrar et al. 2009). In addition, SBDS has extra-ribosomal functions in cell motility and
in stabilizing the mitotic spindle (Stepanovic, Wessels et al. 2004; Wessels, Srikantha et
al. 2006; Austin, Gupta et al. 2008; Orelio and Kuijpers 2009). The multifunctional
character of the SBDS protein may explain the complex clinical phenotypes observed in
SDS patients. The molecular mechanisms by which SBDS functions in these diverse
processes is unknown. In the studies described above, I investigated a novel role for
Sdo 1, the yeast ortholog of the human Shwachman-Diamond syndrome protein, in
modulating protein acetylation via its function as a histone deacetylase inhibitor. The
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pleiotropic nature of this proposed function for Sdo 1 and other members of the SBDS
protein family provide an explanation for their involvement in diverse cellular processes.
A role for Sdol in regulating lysine acetylation was suggested by the observation
that the severe growth defect associated with the loss of Sdo 1 function in yeast was
partially ameliorated by treatment with histone deacetylase inhibitors.

I have since

demonstrated that the HDAC inhibitor, TSA, rescues the slow growth phenotype in a
yeast model of SDS. The impaired growth observed in cells depleted of Sdo 1 is linked to
a defect in the transport of pre-60S subunits from the nucleus to the cytoplasm. This
results in a deficit of functional 60S ribosomal subunits in the cytoplasm and a global
decrease in translation (Menne, Goyenechea et al. 2007; Moore IV, Farrar et al. 2009).
The translational defect is evident by the accumulation of half-mer polysomes (polysome
peaks appearing as doublets) and a marked decrease in polysome size (Moore IV, Farrar
et al. 2009). The polysome profiles of Sdol-depleted strains treated with increasing
concentrations of TSA demonstrate a dose-dependent decrease in the quantity of halfmers and an increased amount of total polysomes (Figure 11). Closer inspection of
polysome profiles revealed that, relative to controls, strains treated with TSA possess a
statistically significant decrease in the pool of free 60S subunits and 80S monomers with
a concomitant increase in polysome size. These data indicate that the amount of 60S
subunits capable of functioning in translation is increased in SDO 1 mutants treated with
TSA relative to untreated cells.
The effects of TSA on SD01-null yeast strains had not been seen previously. In
light of the fact that TSA is a known inhibitor of both class I and class II HDAC
enzymes, these studies suggest that Sdo 1 functions in a pathway that modulates the
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activity of two major histone deacetylases within yeast cells. Given the evidence that
Sdo 1 may function as a natural inhibitor of class I and II HDACs it seemed reasonable to
determine if genetically inactivating one or more of the genes encoding HDACs could
also rescue the Sdo 1 phenotype. In this regard, of the 13 known yeast HDAC genes
investigated, the deletion of RPD3 and HDAl was capable of rescuing the slow growth
phenotype associated with the loss of Sdo 1 (unpublished data; de Figueiredo laboratory
of Texas A&M). This observation suggests that these two HDACs are the major targets
of Sdo I-mediated inhibition. Further, I demonstrated the double deletion of RPD3 and
HDAl also resolved the ribosome maturation defect associated with the depletion of

Sdol. Interestingly, the rescue was greater with the genetic inactivation (Figure 13) than
with pharmacological inhibition (Figure 12), a result likely due to poor cellular uptake of
TSA.

While these studies were ongoing, our collaborators in the de Figueiredo

laboratory demonstrated that Sdol physically interacts with both Rpd3 and Hdal in vivo,
and inhibits their HDAC activity in vitro. Together, these data show that Sdol is an
inhibitor of HDAC activity and regulates 60S ribosomal subunit maturation via its action
on class I and class II HDAC enzymes.
I have shown both the pharmacological and genetic inhibition of HDAC activity
partially resolves the half-mer polysomes caused by a 60S subunit transport defect in
cells depleted of Sdol. These observations suggested a role for lysine acetylation in the
maturation of 60S ribosomal subunits, specifically relating to the transport of 60S
subunits from the nucleus to the cytoplasm.

Consistent with its role as a histone

deacetylase inhibitor, the loss of Sdo 1 is associated with an overall loss of protein
acetylation, as expected in cells with unregulated histone deacetylase activity. The search
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for potential acetylation targets revealed alterations in whole cell extracts between wildtype and Sdol-depleted cells, but the large number of proteins subject to lysine
acetylation precluded their identification using single dimension SDS-PAGE (Figure 14).
In an attempt to enrich for acetylation targets involved in ribosome maturation, I analyzed
crude ribosome fractions (Figure 14) and fractionated polysomes (Figure 15) for targets
influenced by Sdol. Here again the data revealed a surprisingly large number of yeast
ribosomal proteins, of both the 40S and 60S ribosomal subunits, are subject to lysine
acetylation. This finding was confirmed by a recent publication which demonstrated
numerous ribosomal proteins and other components of the translational machinery
components were subject to lysine acetylation in human cells (Choudhary, Kumar et al.
2009). The studies by Choudhary and colleagues also identified additional functional
networks subject to lysine acetylation including networks involved in nuclear transport
(Choudhary, Kumar et al. 2009).
Tif6, the yeast ortholog of mammalian eIF6, is a shuttling factor that plays a
crucial role in ribosome maturation and nuclear export (Menne, Goyenechea et al. 2007).
Tif6 and Sdo 1 are thought to cooperate in 60S ribosomal subunit maturation, with Sdo 1
functioning in the dissociation and concomitant recycling of Tif6 from nascent 60S
ribosomal subunits in the cytoplasm back to the nucleus (Figure 16). In the nucleus, Tif6
plays a role in late steps in pre-rRNA maturation and 60S subunit export. In strains
depleted of Sdo 1, Tif6 relocates from the nucleus to the cytoplasm where it remains
associated with 60S subunits (Menne, Goyenechea et al. 2007). In addition, the inability
of Tif6 to cycle back to the nucleus also results in the nuclear accumulation of pre-60S
subunits (Moore IV, Farrar et al. 2009). Mutations in TIF6 have been shown to suppress
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the slow growth phenotype and ribosome maturation defects in Sdo I-mutant strains by
apparently lowering the affinity of Tif6 for 60S ribosomal subunits (Menne, Goyenechea
et al. 2007). In Figure 17 (panel B), I observed an increased amount of Tif6 in enriched
ribosome fractions obtained from SDO 1-null strains relative to isogenic wild-type.
Moreover, I have showed that the amount of Tif6 in the ribosome fraction was inversely
proportional to the degree of lysine acetylation of ribosomal proteins (Figure 14). These
observations suggest that Sdo 1 may regulate the intracellular trafficking of Tif6 through
an effect on the level of acetylation of ribosomal proteins and that it is through this
mechanism that Sdol is involved in the export of 60S subunits from the nucleus.
A prediction of the foregoing discussion is that TSA will reverse the increased
amount of Tif6 observed in the ribosome fraction of cells depleted of Sdo 1.

This

prediction was confirmed as the amount of Tif6 cosedimenting with ribosome fractions
was reduced in SDO 1-null yeast strains by either treatment with TSA or double deletion
of histone deacetylases (RPD3 and HDA1), an observation suggesting that Tif6 may be
actively recycling from nascent 60S subunits under these conditions. In this regard, our
collaborators at Texas A&M University showed that treatment with TSA shifts the
localization of RPL25-GFP from the nucleus to the cytoplasm in cells depleted of Sdo 1
(unpublished data). Together, these data suggest that the HDAC inhibitory activity of
Sdol modulates the interaction of Tif6 with pre-60S subunits. The proper modulation of
these interactions is important, as the association of Tif6 with pre-60S subunits is
necessary for late stages in their maturation and the release from 60S subunits is required
for their translational activation in the cytoplasm (Basu, Si et al. 2001; Menne,
Goyenechea et al. 2007). These studies raise a number of questions such as whether Tif6
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is itself a target of Sdo I-regulated acetylation or if one or more other protein targets of
Sdo I-regulated acetylation control the interaction of Tif6 with pre-60S subunits.
The finding that the Sdol protein functions as an inhibitor of HDAC activity,
which is involved in ribosome maturation, represents a novel function for lysine
acetylation of proteins. As their name implies, the primary targets of HDACs have long
been thought to be histones. Acetylation of lysine residues is associated with a loss of
positive charge and so is thought to weaken the binding of basic histone proteins with
negatively charged DNA. In this regard, acetylation of lysine residues in histones results
in reduced nucleosome structure and increased transcriptional activity.

Thus, as a

regulator of lysine acetylation, Sdol could have other potential functions within cells.
Previous studies utilizing large-scale proteomic approaches to characterize multi-protein
complexes in yeast have revealed potential interactions between Sdo I, chromatin
structural components, and chromatin regulatory proteins. For instance, Sdo 1 interacts
with Hta2p, a histone H2A SUbtype, and has been shown to reside in a complex of
proteins containing the histone deacetylase Rpd3 (Krogan, Cagney et al. 2006).
Interestingly, Meskauskas and colleagues demonstrated the loss of Rpd3-associated
histone deacetylase function in yeast to disrupt pre-rRNA processing (Meskauskas,
Baxter et al. 2003). These data suggest that Sdol may influence ribosome biogenesis at
multiple points in this complex pathway.
A multitude of biological mechanisms exists by which Sdo I may influence
ribosome biogenesis

VIa

its ability to modulate HDAC activities.

HDACs have a

tremendous influence on chromatin structure and thus could modify the transcriptional
activity of genes encoding ribosomal RNAs and proteins. Both Rpd3 and Hdal are
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members of distinct HDAC complexes that function to regulate both chromatin silencing
and transcriptional activation of a number of target genes (Thiagalingam, Cheng et al.
2003; Yang and Seto 2008). Interactions between Rpd3 and RP promoter elements have
been reported (Kurdistani, Robyr et al. 2002; Robert, Pokholok et al. 2004) and, UBF, a
major regulator of Pol I-mediated rRNA transcription, is regulated by acetylation
(Pelletier, Stefanovsky et al. 2000).
A recent publication, which analyzed the human acetylome using high-resolution
mass spectroscopy, revealed that over 1,500 proteins are subject to lysine acetylation
(Choudhary, Kumar et al. 2009). Further, many of the proteins identified in this screen
are constituents of functional networks including the ribosome, nuclear transport, actin
cytoskeleton remodeling, cell cycle, and DNA damage repair. These observations offer a
potential explanation for the complex clinical phenotypes of many SDS patients and
highlight a potential molecular process whose disruption could explain the basis for many
of the diverse cellular processes affected in SDS (i.e. ribosome maturation, chemotaxis,
mitotic spindle stabilization, and p53 expression) (Dror 2002; Elghetany and Alter 2002;
Austin, Gupta et al. 2008; Moore IV, Farrar et aI. 2009; Orelio and Kuijpers 2009).
Our data suggests that Sdol modulates the activity of both Rpd3 (class I) and
Hdal (class II) HDACs. Of the yeast HDACs, Rpd3 and Hdal have the highest degrees
of sequence similarity with the mammalian class I histone deacetylase, HDACI and the
mammalian class II histone deacetylase, HDAC6, respectively.

HDAC6 is a major

mammalian cytoplasmic HDAC whose activity targets the acetylation of numerous
cytoskeletal elements, including both tubulin and cortactin (a protein involved in actin
remodeling) (Zhang, Li et al. 2003; Gao, Hubbert et al. 2007; Tran, Marmo et al. 2007;
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Zhang, Yuan et al. 2007). Alterations in the acetylation status of cortactin and tubulin as
mediated by HDAC6 influences the dynamics of cell motility (Zhang, Yuan et al. 2007)
and cellular adhesion (Tran, Marmo et al. 2007), respectively. The influence of tubulin
acetylation on spindle stabilization and genomic stability has not been investigated.
Another interesting target of lysine acetylation is the tumor suppressor p53, which is
overexpressed in the bone marrow of SDS patients (Dror 2002). Mammalian HDACs 1,
2, and 3 decrease the transcriptional activity of p53 via deacetylation (Juan, Shia et al.
2000). These findings suggest that SBDS-mediated inhibition of histone deacetylase
activity may also influence the regulation of p53 activity, which may be a contributing
factor to the pathology observed in SDS.
The demonstration that the pharmacological inhibition of HDAC activity can
partially compensate for the loss of Sdo 1 in cell growth and ribosome biogenesis
establishes a molecular foundation for the potential use of histone deacetylase inhibitors
as a treatment for Shwachman-Diamond syndrome. Many HDAC inhibitors are currently
in phase I-III clinical trials for use in the treatment of solid tumors and hematological
malignancies (Munster, Marchion et al. 2009), and some have recently been licensed by
the US FDA for the treatment of cutaneous T-cell lymphoma (i.e. Vorinostat and
Romidepsin). Although their therapeutic modes of action are not well understood, many
HDAC inhibitors inhibit proliferation of cancer cells by inducing cell cycle arrest,
differentiation, and apoptosis (Marson 2009). Our work identified lysine acetylation as a
process affected by the loss of members of the SdollSBDS family of proteins. The
pleiotropic effects of the disruption of this vital post-translational modification could
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potentially explain how ribosome biogenesis, genome stability, and neutrophil
chemotaxis could all be affected in SDS.
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CHAPTER IV
CONCLUDING REMARKS

The current scientific consensus that ribosome synthesis is the principle molecular
target in both Diamond-Blackfan anemia and Shwachman-Diamond syndrome provides a
potential explanation for their common clinical features and raises questions concerning
the foundation for their unique characteristics (Liu and Ellis 2006; Gregory, AguissaToure et al. 2007; Menne, Goyenechea et al. 2007). In my work, I uncovered distinct
molecular mechanisms by which yeast models of DBA and SDS influence 60S ribosomal
subunit maturation. These observations point to potentially divergent signaling pathways
that may form the basis for the distinct clinical features of these disorders.

Further

studies on the involvement of Sdol in 60S subunit maturation, from its perspective role
as a regulator of protein acetylation in the SDS model, have established a molecular
foundation for the potential use of histone deacetylase inhibitors as a therapeutic
treatment for Shwachman-Diamond syndrome.
DBA is caused by mutations in genes encoding ribosomal proteins of both the
40S and 60S ribosomal subunits. To facilitate comparison with the yeast model of SDS,
which is known to affect 60S subunit maturation, I created a yeast model of DBA that
also affected maturation of 60S subunits. In both models, deficits of functional 60S
subunits were observed. These deficits, however, were created by distinct mechanisms.
Delays in pre-rRNA processing occurred at earlier stages in 60S ribosomal subunit
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maturation in the DBA model compared to that of the SDS model.

This delay, a

consequence of abortive ribosome assembly, was associated with rapid degradation of
assembly intermediates and the concomitant liberation and accumulation of substantial
quantities of extra-ribosomal 5S rRNA. As previously noted, a potential mechanism by
which abortive ribosome assembly (nucleolar stress) could signal to activate the p53
tumor suppressor involves the binding of certain ribosomal proteins with its negative
regulator, MDM2.

As 5S rRNA (in complex with Rpl5 and Rp111) has been

demonstrated to inhibit MDM2 and activate p53 in mammalian cells (Horn and Vousden
2008), these findings have implications for 5S rRNA-mediated stress signaling and p53
activation in DBA. RPL33A, used to create the yeast DBA model, is an ortholog of
RPL35A, which was the first large subunit RP known to be affected in DBA (Farrar,

Nater et al. 2008). My data indicate that haploinsufficiency for Rpl35A could disrupt
large subunit assembly, liberating the 5S rRNA ternary complex making it available for
interactions with MDM2 (Figure 18).

Inhibition of MDM2, in turn, could lead to

apoptosis and cell cycle arrest in a p53-dependent fashion. The ternary complex involved
in signaling through MDM2 may arise from newly synthesized particles that fail to be
properly assembled into newly maturing 60S ribosomal subunits in the absence of
Rp135A or from complexes released from partially assembled assembly intermediates
destined for degradation.
A related signaling mechanism has also been proposed for DBA cases caused by
defects in the assembly of small subunit proteins.

Fumagalli and colleagues

demonstrated the disruption of 40S subunit maturation leads to the translational up-
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A proposed mechanism for nucleolar stress signaling in cells

haploinsufficient for Rp135A.

RPL35A haploinsufficiency in DBA results in 60S

ribosomal subunit abortive assembly, accumulation of extra-ribosomal SS rRNA-RpISRp111 ternary subcomplex, and successive signaling through the MDM2-pS3 axis. Top,
wild-type 60S subunit assembly with ribosomal subunit proteins shown as colored ovals
and rRNA as grey-curvy lines. Ribosome assembly occurs in a hierarchical fashion with
some RPs binding directly to rRNA, facilitating the assembly of additional proteins as
rRNA folds into the functional active sites required for protein synthesis on the ribosome.
Bottom, Rp13SA (L3S) haploinsufficiency disrupts the assembly process, preventing
productive interactions with later assembling ribosomal proteins.

This results in the

diversion of the SS-LS-Lll ternary subcomplex from its normal assembly into 60S
subunits to a potential interaction with MDM2 and subsequent pS3 activation.
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regulation of Rplll, which is necessary for p53 activation (Fumagalli, Di Cara et al.
2009).

Whether Rpl5 and 5S rRNA also participate in this signaling mechanism is

unknown. In light of previous studies in mice and zebrafish models of DBA, which
exhibited a p53-dependent disease phenotype (Danilova, Sakamoto et al. 2008;
McGowan, Li et al. 2008), I believe the nucleolar stress pathway described here that links
abortive ribosome assembly to p53 activation could be a major contributor to the proapoptotic phenotype of erythroid progenitors in DBA patients.
In contrast to the DBA model, the yeast SDS model affected a later step in 60S
ribosomal subunit maturation resulting in the accumulation of relatively stable pre-60S
particles containing associated 5S ribosomal RNA. These particles were largely retained
in the nucleus. Consequently, the SDS model exhibited a reduced accrual of extraribosomal 5S rRNA compared to that of the DBA model, an observation which when
extended to mammalian cells would suggest that nucleolar stress signaling via the
interactions of the 5S rRNA subcomplex with MDM2 may have less significance in SDS
disease pathophysiology.
The recent observation that histone deacetylase inhibitors partially rescue the
severe growth defect of strains depleted of Sdo 1 suggested a role for lysine acetylation in
the pathophysiology of SDS (Guo, Knight et al. 2009). Here I demonstrated both the
pharmacological and genetic inhibition of major class I (RPD3) and class II (HDA1)
families of yeast HDAC enzymes partially resolve the ribosome maturation defect in cells
depleted of Sdo 1. These observations are not only the first to show a role for lysine
acetylation in the maturation of 60S ribosomal subunits, but are also the first to reveal a
novel role for Sdol as a modulator of cellular HDAC activities. In my analyses, the
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inhibition of HDAC activity in the absence of Sdol increased the number of functional
60S ribosomal subunits reaching the cytoplasm. These findings were corroborated with
fluorescence studies in SDO i-null yeast strains, which demonstrated a relocalization of
RPL25-GFP from the nucleolus to the cytoplasm in the presence of TSA (unpublished
data; Texas A&M University).

Together, our work suggests that SBDS-mediated

inhibition of cellular HDAC activities in human cells may also be necessary for efficient
nuclear export of 60S ribosomal subunits (Figure 19).
The inverse relationship between ribosomal protein acetylation and Tif6
association with 60S subunits suggests that in the absence of Sdo 1, the inability to release
Tif6 from cytoplasmic 60S subunits interferes with Tif6 recycling and subsequent
functions in subunit export from the nucleus. I showed that the enhanced association of
Tif6 with 60S ribosomal subunits in Sdo I-deficient yeast strains is reduced by either
pharmacological inhibition or genetic inactivation of Rpd3 and Hdal. The mammalian
ortholog of Tif6, eIF6, is also required for 60S subunit biogenesis, and like its yeast
counterpart also functions as an anti-association factor, preventing 40S and 60S subunits
from non-productive interactions (Donadini, Giacopelli et al. 2006). This data suggests
that eIF6 may also need Sbds-mediated inhibition of HDAC activity for efficient release
of eIF6 from nascent 60S ribosomal subunits in the cytoplasm.
The demonstration that lysine acetylation targets numerous protein complexes and
that this modification likely regulates many major cellular processes (Choudhary, Kumar
et al. 2009) underscores the potential polyfunctional character of the SBDS family of
proteins and places emphasis on a molecular process whose loss of function in SDS could
be responsible for the complex clinical features of the disease. These functions include
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Figure 19. A model showing a role for Sbds-mediated regulation of cellular histone

deacetylase activity in the efficient export of pre-60S ribosomal subunits from the
nucleus to the cytoplasm. Top, wild-type 60S subunit maturation in the presence of
wild-type SBDS.

The late steps of 60S ribosomal subunit maturation require Sbds-

mediated inhibition of deacetylase activity to facilitate transport from the nucleus to the
cytoplasm. Bottom, the loss of Sbds is associated with unregulated deacetylase activity,
which results in inefficient export of 60S ribosomal subunits to the cyctoplasm.
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impaired neutrophil motility and chemotaxis, mitotic spindle destabilization and genomic
instability, and as my data suggests, aberrations in ribosome maturation (Dror 2002;
Elghetany and Alter 2002; Austin, Gupta et al. 2008; Moore IV, Farrar et al. 2009; Orelio
and Kuijpers 2009).
The work presented here clearly illustrates different molecular mechanisms in 60S
ribosomal subunit maturation between yeast models of DBA and SDS. The molecular
differences presented in these models may actually form the basis for various types of
nucleolar stress signaling and are likely a contributing factor to the unique clinical
features of these two human disorders. Beyond its ability to influence the intracellular
trafficking of Tif6 and ribosome maturation, the ability of Sdo 1 to modulate protein
acetylation through the inhibition of histone deacetylase activity implicates the
involvement of the SBDS family of proteins in other diverse cellular processes. Finally,
these studies strongly suggest that HDAC inhibitors may be of therapeutic benefit to
patients suffering from Shwachman-Diamond syndrome.
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Introduction
Initial Remarks

Some experimental results acquired throughout the course of my dissertation
work, which provided additional contrasting molecular features between the yeast models
of DBA and SDS, were omitted from the main body of presented work. This was chiefly
due to changes in research aims and/or experimental focus. As a result, some studies and
supporting experiments were not completed or were deemed unnecessary for inclusion
into dissertation chapters for reasons that it would potentially distract from this work's
intended line of reasoning. Despite this, some of the experiments and resulting data not
included in the main body of this dissertation contributed to the conclusions of the work
presented here and therefore are shown in the appendix.

Below, these data will be

explained in the context of the previous work described.

Review of DBA and SDS Clinical Features

Shwachman-Diamond syndrome and Diamond-Blackfan anemia are members of
a rare group of genetic disorders classified as inherited bone marrow failure syndromes
(IBMFS) with clinical presentations most notably involving hematological abnormalities
and generalized growth delays. Both diseases (manifest in early infancy) present with
heterogeneous clinical phenotypes involving a wide range of congenital anomalies and
predisposition to cancer. Although SDS and DBA share certain overarching features,
they differ immensely in their clinical manifestations. SDS patients exhibit multisystem
abnormalities which include intermittent or persistent neutropenia, skeletal abnormalities
(i.e. metaphyseal dysostosis), and exocrine pancreatic insufficiency.
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Moreover,

retrospective studies of SDS patients reveal a high propensity for malignant
transformation into myelodysplastic syndrome and acute myeloid leukemia (25-33% of
patients) (Alter 2007; Coccia, Ruggiero et al. 2007). Conversely, DBA patients present
with an erythroid hypoplasia (anemia) and display variable congenital anomalies
including abnormal or triphalangeal thumbs, craniofacial anomalies, and cleft palate.
DBA patients exhibit an overall lower incidence of cancer (0.5-6.6% of patients) and
have a predisposition to solid tumors (i.e. osteosarcoma) in addition to hematopoietic
malignancies (Alter 2007; Vlachos, Ball et al. 2008).

Overview of Disease Etiology

Given that DBA and SDS exhibit distinct clinical phenotypes, it is intriguing to
find that the molecular bases for both diseases converge on a common target - the
ribosome. Several genes are mutated in DBA, all of which encode structural components
of the ribosome. Moreover, both small and large subunit proteins have been described in
the literature, many of which have been shown to be required for biogenesis of their
respective subunit. For example, early studies in yeast indicated that RPS19, the first
gene identified as mutated in DBA, is required for the maturation of 40S ribosomal
subunits. Yeast cells deficient in RPS19 have a marked reduction in the steady-state level
of 40S ribosomal subunits and compromised protein synthetic capacity (Liu and Ellis
2006). Moreover, siRNA knockdown of RPS19 in human cell lines (TF-I and HeLa)
provide additional support to its already suggested role in 40S subunit biogenesis
(Choesmel, Bacqueville et al. 2007; Flygare, Aspesi et al. 2007). These data provide
substantial evidence to implicate DBA as a disorder resulting from a failure to produce
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adequate quantities of ribosomes. Given that RPS19 is required for the maturation of 40S
subunits, questions now remain as to how haploinsufficiency for an essential ribosomal
protein results in a DBA phenotype characterized by defective differentiation of proerythroblasts and pro-apoptotic hematopoiesis.

While a number of affected genes

encoding ribosomal proteins have been implicated in DBA, only one gene has been found
to be mutated in SDS, SBDS. The SBDS gene, though not a structural component of the
ribosome, associates with 60S ribosomal subunits (Ganapathi, Austin et al. 2007). Its
true function, to date, is still not completely clear, though, considerable evidence from
both yeast and mammalian based studies implicate SBDS in 60S ribosomal subunit
biogenesis (Menne, Goyenechea et al. 2007; Ball, Zhang et al. 2009; Moore IV, Farrar et
al. 2009). Indeed these data suggest that both DBA and SDS converge on deficiencies in
ribosome synthesis and/or function in their disease pathophysiology, but specifically how
these ribosome based defects lead to the common and distinct clinical phenotypes among
these two disorders have yet to be determined.

Nucleolar Stress Signaling in DBA
Recent studies in the DBA field led to the discovery of a signaling pathway that
could potentially bridge the gap between the failure to synthesize adequate amounts of
ribosomes and the pro-apoptotic phenotype of erythroid progenitors in DBA patients.
This nucleolar stress signaling pathway is thought to proceed via direct interactions of
unassembled ribosomal proteins with proteins moderating cell cycle progression and
apoptosis.

It is believed that when ribosome synthesis is disrupted, these proteins

become free to act as molecular messengers to activate pathways (MDM2) leading to the
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stabilization and activation of pS3. The role of pS3 in the context of this pathway has
been documented in a zebrafish model of DBA (Danilova, Sakamoto et al. 2008). To
date, three large ribosomal proteins (RpIS, Rp111, and Rp123) have been shown to
activate pS3 by acting directly on MDM2 (Dai and Lu 2004; Dai, Zeng et al. 2004).
While appealing, this model does not explain how other disorders linked to ribosome
biogenesis have clinical phenotypes distinct from DBA. SDS has been reported to be
connected to defects in 60S subunit biogenesis and, as my data suggests, may induce
nucleolar stress as well. However, DBA and SDS clinical features are distinct and thus
nucleolar stress signaling alone would not likely be sufficient to explain these observed
clinical differences. In chapter II, I turned to yeast models of these two disorders to
mechanistically dissect how these ribosome-based syndromes affected both ribosome
formation and function in an effort to elucidate common and distinct pathways leading to
clinical divergence. My results reveal that both models differ in terms of their effects on
subunit assembly and stability, and their potential for subsequent induction of nucleolar
stress.

Translational Alterations
In this dissertation's work, I exploited yeast deletion strains of the orthologs of
those human genes identified to affect the 60S subunit in DBA and SDS, RPL33A and
SD01, respectively. Each disease model shows defects in 60S subunit maturation, but

with distinct underlying mechanisms.

In the DBA model, 60S subunit maturation is

disrupted at a relatively early stage with abortive complexes subject to rapid degradation.
In contrast, subunit maturation in the SDS model is affected at a later step, giving rise to
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relatively stable pre-60S particles that are notably retained in the nucleus. Moreover,
with respect to the SDS model, we revealed that Sdo 1 functions in 60S subunit
maturation via modulating histone deacetylase activities. These studies have elucidated
differing mechanisms between the two models by which the translational machinery is
affected, albeit both demonstrating 60S subunit deficits. The differences between the
yeast DBA and SDS models have implications for signaling mechanisms linking abortive
ribosome assembly to cell fate decisions and may contribute to the divergent clinical
presentations of DBA and SDS. Despite this, I believe that the differences in clinical
phenotypes between SDS and DBA may also result from their diverse effects on the
translation of varying cellular mRNAs. Early studies supporting this notion demonstrated
that alterations in polypeptide chain initiation components could alter, in a predictable
manner, the relative translation of certain mRNAs (Lodish 1974). Here I show some data
that demonstrates the yeast DBA and SDS models, which have unique ribosome based
defects, to have differing affects on translational output.

SDS and Apoptosis
Increased apoptosis has been implicated as a central pathogenic mechanism in
both DBA and SDS.

However, little is known concerning disease specific cellular

mechanisms leading to apoptosis and more importantly, reasons for hematopoietic
lineage specificity.

Nucleolar stress has been implicated in DBA where ribosome

assembly is clearly affected, and could be a contributing factor in SDS as well. However,
others have demonstrated increased expression of Fas antigen and hyperactivation of the
Fas signaling pathway in SDS hematopoietic progenitors (Dror and Freedman 2001).
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This extrinsic pathway may contribute to the faulty proliferative properties and proapoptotic phenotype of SDS hematopoietic progenitors; however, it does not address the
basis for the hematopoietic lineage specificity associated with the disease whereas the
major hematologic defect in SDS is neutropenia. Thus, questions linger as to whether
this observation is due to neutrophil progenitors undergoing apoptosis prior to complete
maturation or due to the activation of additional apoptotic signaling pathways.

My

preliminary studies have shown the SDS yeast model exhibits a significant increase in the
mitochondrial porin protein termed PorI. The human ortholog of the gene encoding this
protein is VDAC1, a voltage-dependent anion channel that is a subunit of the
mitochondrial polyprotein channel called the permeability transition pore (PTP).
Interestingly, the PTP is implicated in mediating the release of apoptogenic intermediates
such as cytochrome c from the intermembrane space, which appears to be a central event
in the initiation of the cascade leading to programmed cell death (Zaid, Abu-Hamad et al.
2005).

Previous studies have shown increased VDACl expression correlates with

increased sensitization of human hematopoietic cells to various extracellular stimuli
leading to apoptosis (Liu, Ishikawa et al. 2006). The yeast SDS model introduces the
potential involvement of intrinsic mitochondrial pathways leading to apoptosis in SDS
pathogenesis.

Supplemental Results

The Influence of SDOl and RPL33A Deletion on the 20S Replicon
The work presented in chapter II revealed unique effects of SDOl and RPL33A
deletion on the translational machinery of cells. The goal was to determine whether these
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mechanisms were sufficiently distinct to account for the different clinical phenotypes.
One way I addressed this issue was by examining how these different mechanisms
influenced translation in each model.
Both yeast disease models displayed a subAOS peak in their polysome profiles
that was present in much reduced amounts in their corresponding wild-type strains. This
peak corresponds to a yeast endogenous single-stranded RNA virus, termed the 20S
replicon or 20S RNA. The 20S RNA is a noninfectious virus found in most laboratory
strains of the yeast Saccharomyces cerevisiae and encodes a protein (91 kDa), which
non-covalently associates with the RNA and is responsible for its replication (Widner,
Matsumoto et al. 1991; Garcia-Cuellar, Esteban et al. 1997). The 20S RNA lacks both a
5' cap and a poly (A) tail, and the host antiviral system maintains a low copy number of

the 20S replicon via a high rate of turnover of the 20S RNA and by inefficient translation
of the 20S RNA encoded polymerase. Mutations in a number of yeast genes affect the
copy number of the 20S replicon, and interestingly, a number of these involved mutations
in genes encoding proteins of the 60S subunit; mutations in these genes result in
decreased 20S replicon copy number (Ohtake and Wickner 1995). In contrast to these
earlier studies, my results demonstrated the copy number of the 20S replicon to increase
in both !1RPL33A and !J.SDOl strains compared to their respective wild-types (Figure
SI).
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Figure S 1. Deletion of SDOI or RPL33A results in an increase in the 20S replicon

copy number. (A) Northern blot analyses of 20S RNA or U3 snoRNA derived from

!1SD01, !1RPL33A, or isogenic wild-types strains.

Total RNA was isolated from

aforementioned yeast strains, resolved on 1.5% formaldehyde-agarose gels, transferred to
nylon membranes, and hybridized with oligonucleotides (specific to 20S RNA or U3
snoRNA) labeled at their 5' ends with 32[p]. (B) Bar graph denoting 20S replicon copy
number in !1SD01, MPL33A, and isogenic wild-type strains, which are reported as ratios
of 20S RNA:I3-actin mRNA. Error bars representing standard error of the mean (SEM)
are present.
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In figure S 1, the 20S replicon copy number is quantified for both yeast deletion
strains. These data reveal the copy number of this virus is greatly enhanced in the disease
models compared to their respective wild-types. Moreover, the magnitude of induction
appears greater in the SDS model than that of the DBA model, though this is not
statistically significant and is likely the result of low sample numbers. I demonstrated
that both disease models possess greater copy numbers of 20S RNA compared to
isogenic wild-types, and as a result, I sought to determine if this observation was a
consequence of altered translation of the 20S replicon-encoded polymerase. I did so by
comparing the relative distribution of the 20S replicon in fractionated polysomes from
mutant versus wild-type cells. A different abundant cellular message,

~-actin,

was used

as a control (Figure S2).
The data in figure S2 show that the distributions of 20S replicon in those fractions
representing the polysome region remained relatively unchanged in the SDS model
compared to the wild-type.

Conversely, the polysome distributions of actin mRNA

shifted to fractions containing smaller polysomes in the SDS model relative to the wildtype. The data on the distribution of the actin mRNA was consistent with the general
decrease in translation observed in !1SDOl polysome profiles. As previously mentioned,
the distribution of the 20S replicon RNA did not change between the wild-type and the
!1SDOl strain. This indicates that the 20S replicon RNA competes more efficiently than

other cellular messages for the limiting translational machinery in the !1SDO 1 strain and
thus, its translation could be enhanced relative to the bulk mRNA. I had planned to
address this same question in the yeast DBA model using the same methodology
described above, however this was not pursued due to adjustments in research focus.
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Figure S2. The 20S replicon RNA competes more efficiently than other cellular

messages for the limiting translational machinery in the ASDOl strain.
Distribution of 20S replicon and

~-actin

(A)

in fractionated polysomes from wild-type (left)

and I1SDOl (right) strains. Northern blot analysis of RNA recovered from fractionated
polysomes profiles are depicted below, which utilized radiolabeled oligonucleotide
probes specific to

~-actin

or 20S replicon. (B) Quantification of the distributions of 20S

replicon (bottom panel) and

~-actin

(top panel) from fractionated polysomes of both

wild-type (blue bars) and I1SDOl (red bars) strains. Y-axis denotes % relative intensity
of Northern blot signals quantified from individual fractions. X-axis denotes individual
fractions and relative sucrose gradient concentrations (%).
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Broad Analysis of Translational Output of Yeast DBA and SDS Models
The increase in the copy number of the 20S replicon appeared to be a response to
general translational stress that does not distinguish between the two disease models. For
this reason, I carried out a more broadly based analysis of translational output in the DBA
and SDS yeast models in an effort to identify proteins that are selective to either of these
specific models.

Yeast strains were pulse labeled with eSS]-methionine and newly

synthesized proteins were resolved by both one and two-dimensional gel electrophoresis
(Figure S3). A number of proteins in the SDS-PAGE gel were reduced and enhanced in
the two mutants relative to their respective wild-types. Interestingly, an unknown protein
with an approximate molecular weight of 30 kDa was greatly enhanced in the I'1SDO 1
strain relative to wild-type using conventional one-dimensional SDS-PAGE gel analysis
(Figure S3, Panel A). Further analysis of this protein was performed by two-dimensional
gel analysis of normalized total protein extracts isolated from the I'1SDOl and
corresponding isogenic wild-type yeast strains (Figure S3, Panel B).

The enhanced

expression of the 30 kDa protein in the I'1SDO 1 yeast strain was apparent by both
autoradiography (Figure S3) and Colloidal Coomassie Blue staining. MALDI-TOF mass
spectroscopic analysis of the excised 30 kDa protein from 2D gel analysis identified this
protein to be the post-transcriptionally regulated protein known as Pori (a mitochondrial
voltage-dependent anion channel).

134

A

IlJ

r:'J~

ty>

ty>

~~ ;) o~
_::-..b ~ 0<:)

.s;."

B
Por1

wild-type

Llsdo1

37kDa2SkDa-

75kOa
37kDa
20kOa

acid ic

basic

135

acidic

basic

Figure S3. Yeast DBA and SDS models have differential effects on translational

output. (A)

Autoradiograph of S35 -labeled newly synthesized proteins resolved on

single dimension SDS-PAGE gels.
incubated for 30 minutes with

Wild-type, MPL33A, or I1SDOl strains were

e5S]-methionine, total protein isolated (Yaffe-Schatz

method), and resolved using a standard 12% SDS-PAGE gel. A red arrow highlights an
unknown protein band at -30 kDa in the I1SDOl strain. (B) Autoradiograph of S35_
labeled newly synthesized proteins resolved using 2-dimensional gel electrophoresis.
Wild-type (left panels) or I1SDOl (right panels) strains were incubated for 30 minutes
with

e5S]-methionine,

cells mechanically lysed with glass beads, and total protein

extracts finally resolved by 2D gel electrophoresis.

Proteins underwent isoelectric

focusing on immobilized pH gradients that ranged from pH 3-10. The second dimension
was resolved via a 4-12% gradient polyacrylamide gel.

Molecular masses for size

standards are shown to the left. Regions enclosed by the boxes are expanded above each
gel.

The spot labeled Porl was excised and identified via MALDI-TOF mass

spectroscopy.
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Mechanisms of PORi's Enhanced Expression in Yeast DBA and SDS Models
As two-dimensional gel analysis qualitatively revealed differences in the
abundance of PorI protein among the SDS and DBA yeast models, I subsequently used
western analysis to analyze the relative quantities of PorI in both disease models.
Western blots showed this protein to be more abundant in mutant cells (DBA and SDS
yeast models) compared to their respective wild-type controls, but appeared to differ
greatly in quantity between the two disease models (Figure S4); PorI was induced to a
much greater extent in the SDS strain than in the DBA strain. I next wanted to determine
whether the enhanced expression of PorI was a consequence of differences in
transcription or translation. Northern blotting revealed similar increases in POR1 and

~

actin cellular messages in mutants compared to respective wild-type strains suggesting
that the observed selective increase in PorI protein in the SDS model was mediated at the
post -transcriptional level (Figure S4).
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Figure S4. Selective induction of the PorI protein in the ASDOI yeast strain. (A)
Immunoblot of whole cell extracts from wild-type,

~RPL33A,

and

~SD01

strains. Blots

were probed with anti-sera raised to either Porl or p-actin. (B) Total RNA was isolated
from the strains listed and hybridized with radiolabeled oligonucleotide probes specific to
POR1 or p-actin mRNA. Quantification of (C) Porl immunoblots (reported as relative

signal intensity) and (D) POR1 mRNA Northern blots (reported as ratios of signal
intensity of POR1:p-actin mRNA) from wild-type, MPL33A, and

~SD01

yeast strains.

Error bars representing standard error of the mean (SEM) are present in bar graphs.
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To determine if the enhanced expressIOn of Porl corresponded to enhanced
translational efficiency of the paR] message in the yeast disease models, I examined the
relative distribution of the paR] mRNA in fractionated polysomes from mutant versus
wild-type cells. I began these studies on the yeast SDS model and its related wild-type
(Figure S5). As was expected, the actin mRNA shifted from larger to smaller polysomes
in the I1SDO] strain compared to the wild-type strain, consistent with the general
translational stress observed in the SDS model. Moreover, an unexpected shift of the
paR] message from larger to smaller polysomes was observed in the SDS model

compared to wild-type, similar to what was observed for the p-actin control. Thus, at the
present, the translation of paR] mRNA does not appear to be enhanced in the I1SDO 1
strain. This observation needs to be confirmed, and if so, may suggest an effect of the
SDO] mutation on Porl protein stability.

Concerning these observations, I have not

repeated these experiments in either disease model nor pursued additional methods to
address the mechanisms leading to their enhanced expression of the Porl protein, as this
projects research focus changed directions.
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Distributions of PORl mRNA and actin in fractionated poly somes.

Polysome profiles corresponding to wild-type (left) and !1SDO] (right) yeast strains are
shown. Polysomes were fractionated, RNA collected, and Northern analysis performed
(depicted below absorbance tracings) using radiolabeled oligonucleotide probes specific
to p-actin or paR] rnRNA.
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Conclusions

Northern blot analyses of both DBA and SDS yeast models revealed quantitative
differences in the 20S replicon copy number compared to wild-types, though differences
between the two disease models were not statistically significant. Examination of the
distribution of the 20S RNA in fractionated polysomes from the SDS model revealed that
20S RNA competes much more efficiently in translation in comparison to the
control, whereas

~-actin

~-actin

shifted to smaller polysomes and the 20S replicon remained

unaffected.
PorI immunoblots confirmed its enhanced expression in both disease models
compared to wild-types, however it was much higher in the yeast SDS model.

I

anticipate these increases to correspond to enhanced translational efficiency of the PORi
message. Preliminary results concerning the distribution of PORi message in polysome
fractions, obtained from the SDS model, did not support the notion of its enhanced
translation efficiency; however, these experiments require replication in an effort to
tackle this disparity.

I predict both models will demonstrate increased translational

efficiency of this cellular message, with greater efficiency in the SDS model than in the
DBA model. Northern blot analyses show the relative quantities of PORi message to not
differ among disease models and related wild-types suggesting that this is not a result of
enhanced transcription of PORi. PorI protein stability was not investigated and thus
could be a contributing factor to its enhanced expression in the SDO i deletion strain.
Based on these results, I hypothesize VDACi to be a possible contributor to the proapoptotic phenotype observed in SDS.

The data shown in this dissertation exposed

distinct mechanisms relating to how DBA and SDS yeast models impact the translational
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apparatus of cells.

Further, the supplemental data expands on these observations to

demonstrate that both models have differential affects on the translational output of cells,
which could be an additional factor that contributes to the clinical divergence in DBA and
SDS.
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LIST OF ABBREVIATIONS AND SYMBOLS

[Methyl-3R]-methionine

Tritiated-methyl methionine

20S Replicon or 20S RNA

A yeast endogenous single-stranded RNA virus

5'-TOP

5' terminal oligopyrimidine

5S-L5-Lll ternary
subcomplex

A complex containing 5S rRNA and Rpl5 and Rp111
ribosomal proteins
Absorbance at a wavelength of 254 nanometers

AML

Acute myelogenous leukemia

ARF

Alternative reading frame tumor suppressor

ARXl

Yeast pre-60S shuttling factor

B231NPM

Nuc1eophosmin

BFU-E

Erythroid burst-forming units

CFU-E

Erythroid colony-forming units

CFU-GM

Granulocyte-monocyte colony-forming units

CRR

Cartilage-hair hypoplasia

DAPI

4' ,6-diamidino-2-phenylindole

DBA

Diamond-Blackfan anemia

DBAR

Diamond-Blackfan Anemia Registry

DC

Dyskeratosis congenita

DEPC

Diethyl pyrocarbonate

eADA

Erythrocyte adenosine deaminase activity

ECL

Enhanced chemiluminescence
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EFLl

Yeast cytoplasmic GTPase involved in biogenesis of
the 60S ribosome

ERG6

Yeast delta(24 )-sterol C-methyltransferase (ergosterol
biosynthetic pathway)

ETS

External transcribed spacer

GFP

Green fluorescent protein

HDAl

Yeast class II histone deacetylase

HDAC

Histone deacetylase

IBMFS

Inherited bone marrow failure syndromes

IEF

Isoelectric focusing

IgG

Immunoglobulin G

ITS!

Internal transcribed spacer 1

ITS2

Internal transcribed spacer 2

MALDI-TOF mass
spectroscopy

Matrix-assisted laser desorption/ionization mass
spectroscopy

MDM2

Murine double minute oncogene

MDS

Myelodysplastic syndrome

mRNA

Messenger RNA

Mut

Mutant

NES

Nuclear export signal

NHLBI

National Heart, Lung, and Blood Institute

NMD3

Yeast protein involved in 60S ribosomal subunit
nuclear export (Crmlp-dependent adapter protein)

p53

p53 tumor suppressor

PDR5

Yeast plasma membrane ATP-binding cassette (ABC)
transporter
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PI3K

Phosphotidyl inositol 3-kinase

Poll

DNA polymerase I

Pol II

DNA polymerase II

Pol III

DNA polymerase III

pre-rRNA

Pre-ribosomal RNA

PTM

Posttranslational modification

PTP

Permeability transition pore

RB

Retinoblastoma

rDNA

Ribosomal DNA

RNP

Ribonucleoprotein

RP

Ribosomal protein

RPD3

Yeast class I histone deacetylase

RPM

Revolutions per minute

rRNA

Ribosomal RNA

SBDS

Gene mutated in Shwachman-Diamond syndrome

SBDSP

SBDS paralogous pseudo gene

SDOI

Yeast ortholog of the human SBDS protein;
responsible for Shwachman-Diamond syndrome

SDS

Shwachman-Diamond syndrome

SDS-PAGE

Sodium dodecyl sulfate polyacrylamide gel
electrophoresis

SEM

Standard error of the mean

snoRNA

Small nucleolar RNA
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snoRNP

Small nucleolar ribonucleoprotein

SNQ2

Yeast plasma membrane ATP-binding cassette (ABC)
transporter

TAP

Tandem affinity purification

TIF6

Yeast translation initiation factor 6 (constituent of 66S
pre-ribosomal particles)

TSA

Trichostatin A

UBF

Upstream binding factor

w/v

weight/volume

WT

Wild-type

XP01ICRMl

Yeast karyopherin, involved in export of proteins,
RNAs, and ribosomal subunits from the nucleus
Radiolabeled gamma-phosphate of adenosine
triphosphate
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